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ABSTRACT
Santhanakrishnan, Rajalakshmi. Ph.D., Biomedical Sciences Ph.D. Program, Wright
State University, 2019. Mitochondria-Dependent Cellular Toxicity of α-synuclein
Modeled in Yeast.

Parkinson’s disease is the second most common neurodegenerative disease. This disease
is caused by the degeneration of dopaminergic neurons, leading to debilitating motor
symptoms and early mortality. The protein α-synuclein (α-syn), encoded by SNCA,
misfolds and forms inclusions in Parkinson’s disease brains. When α-syn is
overexpressed in yeast, it causes cellular toxicity and an increased number of aggregates,
recapitulating the toxic phenotypes observed in humans and animal models. Yeast models
are a powerful tool to perform high-throughput overexpression screening to identify
modifiers of α-syn toxicity. α-syn causes mitochondrial dysfunction by inhibiting
complex I and inducing mitochondrial fragmentation. Prior screening of α-syn were
limited to only the galactose condition, where mitochondrial function is dispensable.
Previous screening was performed exclusively with the GAL1 promoter, restricting the
genes to only those induced by galactose. We have validated an overexpression system
using GAL3 alleles that can induce genes under mitochondrial-dependent glycerol-ethanol
condition and other non-galactose conditions (calorie restriction, nitrogen starvation and
raffinose). α-syn showed discrepancy in the correlation of toxicity and aggregation in
non-galactose conditions. Compared to galactose, under glycerol-ethanol condition, α-syn
iv

exhibited higher toxicity, formed more aggregates, and decreased viability and
respiratory competency despite having similar expression under the two conditions. We
screened 14,827 human gene clones and identified 87 that can suppress α-syn toxicity in
glycerol-ethanol. Genes involved in RNA polymerase II function, anterior-posterior axis
and nucleoplasm were overrepresented. Among the suppressor hits, we identified four
14-3-3 protein isotypes (b, g, q, and z). None of the four suppressors suppressed the
toxicity under galactose. However, the 14-3-3 suppressors did not reduce aggregates
under glycerol-ethanol. No increase in respiratory competency was observed; however,
14-3-3b was seen to effectively reduce the number of cells that accumulate ROS. Overall,
we have created an overexpression system that describes a new path for performing
screening in non-galactose conditions. Our results based on novel phenotypes of α-syn
show that screening in these conditions is indeed important. We have identified
previously unknown suppressors of α-syn toxicity and ruled out underlying mechanisms
of action.
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I.

INTRODUCTION

Parkinson’s disease and α-synuclein
Parkinson’s disease is the second most common neurodegenerative disease
worldwide.1 Parkinson’s disease is a motor disorder that presents with three cardinal
symptoms: bradykinesia (slow movement), rigidity, and tremors. Nonmotor symptoms,
including cognitive impairment, autonomic dysfunction, sleep disorders, and depression
also affect the patient’s quality of life. Parkinson’s disease is an aging disease with the
prevalence increasing from 0.3% in the general population, to greater than 4% among
individuals over 85 years of age.2,3 The disease is difficult to treat because once the first
symptoms appear, 60% of motor neurons have already degenerated. As such, the
prevalence of Parkinson’s disease is expected to double by the year 2030,4 adding
tremendously to the ever-increasing medical economic burden associated with the
disease. Furthermore, the mortality rate is double that of the healthy general population,5
with available treatment strategies neither modifying the progression of the disease nor
delaying the onset of disability. Hence, there is an incredible impetus for further research
in this field.6
Neurologically, Parkinson’s disease is characterized by the degeneration of
pigmented dopaminergic neurons in the substantia nigra pars compacta of the midbrain
and histologically, by the presence of Lewy bodies which are intracellular α-synuclein (αsyn) aggregates.7 Although the specific underlying cause of Parkinson’s disease is
unknown, a combination of genetic mutations and environmental factors appear to play a
1

role. Further, over 90% of the disease incidence is sporadic, meaning there is no family
history of disease; while approximately 10% of the disease incidence is familial, meaning
there is a family member who has the disease. There are six genes whose mutations have
been linked to Parkinson’s disease,8 although mutations are responsible for less than 5%
of the overall incidence. Mutations in SNCA and leucine-rich repeat kinase 2 (LRRK2)
genes cause autosomal dominance, whereas those in ATP13A2, Parkin, phosphatase and
tensin homolog-induced kinase 1 (PINK1), and DJ-1 cause autosomal recessive disease.
Autosomal dominant disease is a pattern of inheritance in which an affected individual
has one copy of a mutant gene and one normal gene on a pair of autosomal
chromosomes. Autosomal recessive diseases are caused by two copies of the mutant gene
on a pair of autosomal chromosomes. Individuals with autosomal dominant diseases have
a 50% chance of passing the mutant gene on to each of their children.
SNCA was the first gene identified whose mutations, duplications and triplications
were found to cause Parkinson’s disease.9 SNCA mutations cause early onset (< 50 years
of age) Parkinson’s disease and are associated with high mortality.10 Patients with
triplication of the SNCA have much earlier disease onset and rapid progression compared
with patients with duplication of SNCA.11 The widely studied missense mutations of
SNCA include A30P, E46K, A53T, G51D, and H50Q.12 α-syn protein, encoded by SNCA,
is a small 140-amino acid cytoplasmic protein that belongs to the synuclein family and is
primarily expressed in the brain.13 Mutations, duplications and triplications of SNCA
accelerate aggregation of the α-syn resulting in intracytoplasmic neuronal inclusions
which constitute the Lewy bodies.14,15 Lewy bodies are present in 95% of Parkinson’s
disease brains even in the absence of SNCA mutations.16 Although the precise mechanism
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responsible for initiating the misfolding and aggregaiton of α-syn remains
uncharacterized, environmental and stress factors such as higher pH and temperature, as
well as oxidative stress appear to play a role.
Misfolding and aggregates of α-synuclein cause Parkinson’s disease
α-syn consists of three domains: an amphipathic N-terminal domain, a
hydrophobic center, and a hydrophilic C-terminal domain. This composition results in an
α-helical, random loop formation that facilitates the interactions of α-syn with
phospholipid-containing membranes including those of the mitochondria, endoplasmic
reticulum (ER)/Golgi and the nucleus.17,18 The ability to interact with organelle
membranes makes α-syn a molecular chaperone, enabling docking of synaptic vesicles to
the cell membrane and facilitating intracellular protein trafficking.17,19 Through these
mechanisms, α-syn regulates cellular functions such as neuronal differentiation,20
apoptotic inhibition,21 regulation of synaptic plasticity,22 and regulation of dopamine
release.23
Further, α-syn is an unfolded protein in its native form; however, mutations in
SNCA together with environmental factors (e.g., oxidative stress, pesticide or metal
exposure) cause misfolding of α-syn which then becomes tightly configured in long
filamentous protofibrils and fibrils.24 The distinctive feature of the α-syn aggregation is
the slow primary nucleation process that becomes accelerated when in contact with the
lipid membranes.25 Nucleation involves the formation of a β-sheet core that folds into
itself and aggregates with others to form protofilaments; from the protofilaments, mature
fibrils are formed.26 Under normal conditions, a-syn exists as monomers, which form
soluble oligomers on contact with cellular membranes and then assemble into insoluble
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fibrils when triggered by several stressors (e.g. SNCA mutations, duplications, and
triplications, oxidative stress, metal exposure, etc.,). The cells protective systems,
including the lysosome autophagy system and ubiquitin proteasome system, prevent the
toxic forms from spreading across the neurons resulting in Lewy body formation.27 α-syn,
in its aggregate state, contains five β-sheet cores of amyloid fibrils, each comprised of 35
– 96 amino acid residues (N-terminal amphipathic region). The point-mutations are
primarily located within this core region.26 Missense SNCA mutations can increase the
rates of fibril formation initiation and their proliferation, however, does not affect fibril
elongation.28
ER-associated misfolded protein degradation in yeast
Under normal conditions, the misfolded proteins are processed by the ubiquitin
proteasome system or the autophagy-lysosome pathway.29 The ER plays a major role in
protein quality control. In the ER, once the protein undergoes post-translational
modifications, it must become properly folded before transport to the Golgi apparatus.
Consequently, if the protein becomes misfolded, it will not enter the Golgi but will
instead be redirected to the ER-associated degradation (ERAD) pathway.30,31 There are
four major proteins that make up the ERAD pathway namely, Yos9, Der1, Hrd3, and
Usa1. These four proteins, along with the Hrd1/Der3 (E3 ubiquitin ligase) complex,
recognize the substrate (misfolded protein) at the ER.32 Once recognized, it is
ubiquitinated and Hrd1 mediates the retro-translocation to the Cdc48 complex.33,34
Substrate delivery cofactors Rad23 and Dsk2 aid in further recognition of the substrate by
the 26S proteasome where the deubiquitinating enzymes (Rpn11 and Ubp6) remove the
polyubiquitin chain and are then degraded.35 Perturbations in the ER quality control lead
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to the accumulation of misfolded proteins and cause ER stress. The unfolded protein
response (UPR) pathway is the cell’s protective mechanism against ER stress. UPR is
associated with an increase in ER chaperones, glycosylases and ERAD proteins
(increasing the protein folding capacity) and degradation of messenger ribonucleic acid
(mRNA) (decreasing the protein influx).36 If a large amount of misfolded proteins
accumulate, uncontrolled UPR results in increased production of reactive oxygen species
(ROS) from the ER and mitochondria, which in turn induces caspase-mediated
apoptosis.37
ER stress has been reported in Parkinson’s disease patient brains38 as well as in
genetic models of α-syn overexpression.39,40 In fact, levodopa, a Parkinson’s disease
therapeutic drug, attenuated ER stress in neuronal cell cultures.41 α-syn is not a resident
ER protein; however, it has been shown to consistently interact with the ER, thereby
inhibiting the ER-Golgi transport system in yeast.39,42 Although, the overexpression of αsyn alone did not induce UPR and ER stress, the association between α-syn and the ER
membrane did.40
Additionally, deletion of YCA1, a yeast orthologue of mammalian caspase, leads
to accumulation of damaged cells due to an absence of apoptosis.43 Disruption of UPR or
the deletion of YCA1 did not prevent α-syn mediated apoptosis in yeast; however, yeast
lacking mitochondria (ρ° cells) prevented apoptosis.44 Taken together, these studies
suggest that α-syn may interact with biological membranes and/or synaptic vesicles,
permitting it to transform into an aggregated form which then causes ER stress and
disrupts protein trafficking. The resulting accumulation of misfolded proteins activates
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UPR, increases ROS production and causes caspase-mediated apoptosis that is primarily
dependent on mitochondrial function.
α-synuclein and mitochondrial dysfunction
Mitochondria and a-syn have been independently shown to cause both familial and
idiopathic Parkinson’s disease.45–47 Several studies have shown that a-syn increases
fragmentation of the mitochondria, independent of the mitochondrial fission protein
Dynamin-related protein 1 (Drp1).48 Furthermore, a-syn can localize to the nucleus under
oxidative stress, where it binds to the peroxisome proliferator-activated receptor γ
coactivator 1 α (PGC1α) promoter, thereby decreasing PGC1a-regulated genes and
indirectly affecting mitochondrial function.49 PGC1α is a member of a family of
transcription coactivators that plays a central role in mitochondrial biogenesis. In human
dopaminergic neuron cultures, cell lines and transgenic mouse models, a-syn has been
shown to reduce complex I activity, and increase mitophagy.50–53 Both wild-type (WT)
and mutant a-syn increase ROS production.54–56 Additionally, fluorescence resonance
energy transfer analysis showed that a-syn preferentially interacts with mitochondria
over the ER and other synaptic vesicles.57 Overall, a-syn reduces mitochondrial function
via several mechanisms including, reducing complex I activity, increasing mitochondrial
fragmentation and mitophagy, and accelerating ROS production.
The association of Parkinson’s disease and mitochondria was first reported in the
1980s, when the use of the mitochondrial toxin 1-methyl-4-phenyl-1,2,3,6tetrahydropyridine (MPTP) as an illegal drug was found to lead to the development of
Parkinson’s disease-like symptoms.58 Further, systemic infusion of rotenone (electron
transport chain inhibitor) in animal models59 and mutations in DJ-1, a mitochondrial ROS
6

scavenger, have been shown to cause Parkinson’s disease;60 while mutations in PINK161
and Parkin,62 associated with Parkinson’s disease, cause reduced complex I activity and
adenosine triphosphate (ATP) synthesis. Lastly, a conditional knockout of mitochondrial
transcription factor A in dopaminergic neurons causes respiratory chain deficiency and a
Parkinson’s disease-like phenotype including motor dysfunction.63 It is, therefore,
apparent that mitochondria play a central role in the development and progression of
Parkinson’s disease.
Yeast screening models identified functions of α-synuclein
Researchers have used the yeast Saccharomyces cerevisiae to understand the
mechanisms of α-syn induced cellular toxicity.64 Specifically, when the human SNCA is
overexpressed in yeast under a GAL1 promoter, the toxicity has been found to increase
with increasing copy number.65 Concordantly, the increasing copy number is associated
with increase in the number of intracellular inclusions.66 Moreover, in yeast, mutations or
overexpression of SNCA triggers aggregate formation, inhibit vesicular trafficking, cause
mitochondrial dysfunction, and reduce proteasome degradation, recapitulating the cellular
phenotypes of Parkinson’s disease present in humans.67 In addition, overexpression
screening in yeast has led to the improved understanding of the cellular functions of αsyn that were previously unknown.68 Results of α-syn overexpression screening have
been validated in both in vitro and in vivo neuronal models.69
Two major yeast genetic overexpression screening studies39,42 were performed,
which identified 77 previously unknown genetic modifiers of α-syn toxicity. In these
screens, the transmembrane ATPase Yor291w (yeast homolog of ATP13A2) was
identified as a suppressor of α-syn toxicity; while mutations in ATP13A2 induced
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juvenile onset Parkinson’s disease. Interestingly, yeast were employed to identify the
connections between these two unrelated genes (ATP13A2 and SNCA).42 Indeed,
Caenorhabditis elegans and rat midbrain cultures were used to verify that ATP13A2
antagonized α-syn-mediated dopaminergic neuronal degeneration.42 Further, we now
know that vesicular transport plays a key role in Parkinson’s disease pathology because
of yeast modifier screening. In fact, YPT1, a guanine triphosphatase (GTPase) that
enhances ER-Golgi trafficking, suppressed a-syn toxicity while GYP8, which converts
YPT1 to its inactive state, enhanced a-syn toxicity.39 Yeast screening assays have not
only been used to identify critical cellular perturbations in Parkinson’s disease, but also to
assess the efficacy of therapeutic agents (N-aryl benzimidazole) for the suppression of asyn mediated toxicity.69
Drawback of prior yeast screening models
All screening studies mentioned above were performed exclusively under
galactose growth conditions. Since, SNCA and the yeast genes that were screened were
under the GAL1 promoter, galactose is essential to induce overexpression of these genes.
Galactose is a fermentable carbon source and undergoes glycolysis. Hence, under
galactose conditions, yeast do not require mitochondrial oxidative phosphorylation for
metabolism.70 Given that a-syn affects mitochondria in multiple ways, screening for
modifiers in only galactose conditions would likely cause modifiers of a-syn toxicity
related to mitochondria and the respiratory function of the cell to be overlooked.
Luckily, the ability of yeast to grow on non-fermentable carbon sources (where
mitochondrial function is essential for survival) will allow us to perform screening under
a mitochondrial-dependent growth condition. We sought to develop an overexpression
8

system with the capacity to induce gene expression under non-galactose conditions,
specifically those containing glycerol. Glycerol metabolizes to one molecule of pyruvate
and two nicotinamide adenine dinucleotide hydrogen (NADH). Only one of the NADH
molecules is used to ferment pyruvate to ethanol (Figure 1); while the other NADH
causes a redox imbalance, forcing the NADH to enter the mitochondria for oxidative
phosphorylation,71 making glycerol a mitochondrial-dependent growth condition. We
hypothesized that performing the screening under glycerol-rich conditions will permit the
identification of novel modifiers of a-syn toxicity. This hypothesis was supported by a
yeast screening study examining differences between fermentable and non-fermentable
conditions, which revealed 794 genes to be differentially expressed.72 When cells were
transferred from glucose to glycerol conditions, the transcriptome levels of as many as
1284 RNAs increased. Further, under glycerol conditions, genes involved in
mitochondrial metabolism including those associated with electron transport chain,
oxidative phosphorylation, and tricyclic acid cycle, had increased expression. Thus,
metabolism, gene and protein expression all vary widely between fermentable and nonfermentable carbon source. Since a-syn affects mitochondria, inducing overexpression of
a-syn in glycerol will allow for identification of previously overlooked and interesting
results.
Constitutive GAL3 alleles induce GAL1 promoter in glycerol condition
The GAL1 promoter has an upstream activating sequence that is bound by Gal4p,
the transcriptional activator, which in turn is repressed by Gal80p, the transcriptional
repressor. Under galactose, Gal3p, the protein encoded by GAL3, undergoes
conformational changes whereby it changes from its native ‘open inactive’ conformation
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Figure 1. Glycerol metabolism in yeast
Metabolism of glycerol results in one molecule of pyruvate and two molecules of NADH.
Only one of the two released NADH molecules can be used to ferment pyruvate to
ethanol. The additional NADH causes redox imbalance, forcing the NADH to become
converted to acetyl CoA and enter the mitochondria for oxidative phosphorylation.
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to one that is ‘closed active’. The closed conformation allows Gal3p to bind and remove
Gal80p from Gal4p, resulting in expression of the target gene.73,74 GAL3 alleles had
previously been shown to constitutively induce the GAL1 promoter in glycerol condition
in the absence of galactose by inducing the ‘closed’ conformation of Gal3p.75 We wanted
to test if these alleles can be utilized to induce the GAL1 promoter not just in galactose
but also in other non-galactose growth conditions. GAL1 promoter was preserved because
it provides a simple switch in gene regulation as growth on galactose medium induces
expression, whereas growth on glucose represses expression.76,77 Glucose repression
would help eliminate the problem of cellular toxicity in expressing a-syn. Thus, we chose
three GAL3 alleles (GAL3F237Y, GAL3A368V and GAL3S509P)75 from the previous
publication to test gene induction in non-galactose conditions.
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II.

MATERIALS AND METHODS

Yeast strains, media, and plasmids
Yeast strains, plasmids, and polymerase chain reaction (PCR) primers used in this study
are listed in Tables 1–3, respectively. Yeast cells were grown using standard methods.
Briefly, for integrated strains, including NoTox, IntTox and HiTox a-syn, fused in
sarcoma (FUS), TAR DNA-binding protein 43 (TDP-43), and mutant huntingtin
(HTT103Q), yeast cells were precultured in yeast peptone dextrose (YPD) medium.
Yeast containing free plasmids were precultured in selective medium containing 2%
glucose. Precultures with optical densities between 8–14 at 600 nm (OD600) were washed
with double distilled water and transferred to selective medium containing specific
carbon sources. Mating of yeast strains was performed either in YPD liquid medium or
YPD agar plates. The carbon sources used in this study include 2% glucose, 2%
raffinose, 2% galactose, 0.5% glucose, 0.1% glucose, and 3% glycerol with 1% ethanol.
The nitrogen starvation conditions lacked ammonium sulfate, whereas the other
conditions contained ammonium sulfate (5 g/L). Yeast were incubated at 30 °C either in a
shaker or a stationary incubator for 3 h to 5 d, depending on the experimental
specifications. IntTox a-syn yeast strain was a gift from the Susan Lindquist Lab.
Gateway cloning
The LR reaction is a technique used to transfer entry clone plasmids to yeast
expression vectors, enabling expression of the target gene in yeast cells.78 This reaction
12

included a 10 μL mixture containing 100 ng of entry clone plasmid deoxy-ribonucleic
acid (DNA), 150 ng of destination vector plasmid, 3 µL LR clonase, and Tris EDTA (TE)
buffer. The contents were mixed thoroughly and incubated at 25 °C overnight. Next,
DH5a competent bacterial cells were transformed with 5 µL of the LR reaction mixture
using the bacterial transformation technique. The expression clone was then extracted
from the bacteria using a plasmid miniprep kit according to manufacturer’s instructions
(Zymo Research, California, USA) and confirmed with restriction enzyme digestion
and/or Sanger sequencing.
Site-directed mutagenesis
Primers for GAL3 alleles were designed online using the QuikChange Primer
Design Program available at www.agilent.com/genomics/qcpd (Table 2 and 3). PCR for
mutagenesis was set up by creating a 50 µL mixture containing 5 µL of 10× Pfu reaction
buffer, 50 ng template DNA, 125 ng each of forward and reverse primers, 1 µL
deoxyribonucleotide triphosphate (dNTP), 1 µL Pfu, and double distilled water. Next,
parental DNA from the reaction mixture was digested with DpnI, and 2 µL of the
digested content was transformed into DH5a bacterial cells. A minimum of two, and a
maximum of four bacterial colonies were picked for each allele, and the mutations were
confirmed by Sanger sequencing.
One-step yeast transformation
Yeast were grown overnight and washed twice with distilled water, and 1 mL of
culture was mixed with transformation buffer (80 µL of 50% polyethylene glycol (PEG)
3350, 10 µL of 1 M dithiothreitol, and 10 µL of 1 M lithium acetate).79 No DNA was
added to the negative control; to the remaining samples, 100–200 ng plasmid DNA was
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added to the mixture and incubated in a 42 °C water bath for 1 h. The samples were then
plated on selective agar plates containing glucose or YPD (with or without drugs based
on the plasmid) and incubated at 30 °C for 3 days. Single colonies were isolated, and
glycerol stocks were obtained and used for further experiments.
Yeast mating
Single colonies of yeast strains of opposite mating types with different
auxotrophic markers were streaked on YPD agar plates in a cross pattern and incubated at
30 °C for 16 h. The center of the cross was then streaked to double dropout agar plates.
Plates were incubated at 30 °C for 3 d or until individual colonies were visible. For
library screening, two yeast strains of opposite mating types were freshly grown
separately in selective medium in 96-well plates. Using pins, the two strains were
transferred and mixed in 96-well plates containing 160 µL of YPD. The cells were
allowed to grow overnight to form diploids, which were then transferred using pins into
triple dropout liquid medium containing 2% glucose for selection.
β-Galactosidase assay
A microplate stopped assay protocol was used to perform β-galactosidase assays
(ThermoFisher Scientific, Massachusetts, USA). Briefly, a yeast strain (W303 MATa)
was integrated with the pRS303-LacZ plasmid (Table 2).80 This strain was then mated
with GAL3 allele strains (W303 MATa), resulting in diploid yeast. Single colonies were
grown on double selective 2% glucose medium overnight. Once an OD600 of 0.1 was
observed, cultures were shifted to many growth conditions: 0.1%, 0.5%, and 2% glucose;
2% galactose; 2% raffinose with and without ammonium sulfate; 2% glucose without
ammonium sulfate; and 3% glycerol with 1% ethanol. After the cells reached log phase
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with an OD600 reading between 0.6 and 1.8, 70 µL of the working solution (35 µL βgalactosidase buffer and 35 µL Y-Per reagent) was added to 70 µL yeast culture in each
well, and a timer was started. Duplicates of each culture were used to assess
reproducibility. When a yellow color became visible in the wells, 56 µL of the stop
solution was added to each well, the plates were vortexed for 30 s at 1,000 rpm, the timer
was stopped, and the total reaction time was recorded. The plates were then centrifuged at
1,850 rpm for 5 min, and 160 µL of the supernatant was transferred to flat-bottomed 96well plates. The absorbance at 420 nm (A420) of each well was measured using a
microplate reader (Fisher Scientific, Ontario, Canada) with the well containing water as
the blank. The formula used to calculate β-galactosidase activity was:
β − galactosidase activity =

1,000 x A678
t x V x OD<88

where, t is the time (in min), V is the volume of cells in mL (0.070 mL), A420 is the
absorbance at 420 nm, and OD600 is the optical density at 600 nm.
Serial dilution growth assays
Yeast were grown overnight in YPD or selective medium containing 2% glucose.
Yeast cultures were normalized to an OD600 of 1.0. A 10-fold serial dilution was
performed 4 times, and the diluted samples were spotted in a horizontal pattern on
synthetic agar plates with the following carbon sources: 0.1%, 0.5%, and 2% glucose; 2%
galactose with or without ammonium sulfate; 2% raffinose with or without ammonium
sulfate; 2% glucose without ammonium sulfate; and 3% glycerol with 1% ethanol. Plates
were incubated at 30 °C, and images were collected every 24 h between days 2 and 5.
Western blotting
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Proteins were extracted from yeast cells using a post-alkaline extraction method.81
The extracts were separated by sodium dodecyl sulfate polyacrylamide gel
electrophoresis and transferred to polyvinylidene difluoride membranes, which were then
rinsed with water and blocked with 5% non-fat dry milk in tris-buffered saline with tween
20 (TBST) for 1 h. Incubation with primary antibodies was performed overnight at 4°C.
The membrane was washed five times for 5 min each in TBST and then incubated with
secondary antibodies for 1 h at room temperature. The membrane was washed again five
times for 5 min each in TBST and developed with nitro blue tetrazolium (NBT)/5-bromo4-chloro-3-indolyl-phosphate (BCIP) solution (ThermoFisher Scientific, Massachusetts,
USA). The primary antibodies used were anti-green fluorescent protein (GFP; ab6556,
Abcam, Cambridge, UK) and anti-phosphoglycerate kinase 1 (PGK1; PA5-28612,
Invitrogen, California, USA) at a dilution of 1:10,000. PGK1 is a key enzyme in
glycolysis and gluconeogenesis and localizes to the plasma membrane, mitochondria and
cytoplasm. PGK1 is an essential yeast gene and null mutants are unable to grow in
glucose, galactose or glycerol carbon sources; and thus, it was chosen as the loading
control. The secondary antibodies used were alkaline phosphatase-conjugated anti-rabbit
and anti-mouse antibodies at a dilution of 1:10,000. The experiment was repeated thrice
unless otherwise specified. Image quantification was performed using ImageJ software
with PGK1 as the reference bands.
Fluorescence microscopy
Yeast strains were grown overnight in selective medium containing 2% glucose.
Cultures were centrifuged at 3,900 rpm for 5 min, washed twice with sterile water, and
then resuspended in medium containing either 2% galactose or 3% glycerol with 1%
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ethanol. The cultures were diluted to a starting OD600 of 1.0 and incubated at 30 °C to
induce protein expression for 3–18 h. Cultures were harvested, centrifuged, and
resuspended in sterile water. Three µL of the resuspension were then placed on a
microscope slide with a cover slip. An Olympus IX83 inverted fluorescent microscope
and Olympus DP74 digital camera (Olympus, Japan) were used to capture images at 40×
magnification using fluorescein isothiocyanate, yellow fluorescent protein (YFP), cyan
fluorescent protein (CFP), and Texas Red (Tx Red) filter cubes (chroma 39002, 39003,
49001, and 39010, respectively). Brightfield images were obtained before switching to
other channels.
Quantification of a-synuclein aggregates
The YFP microscopic pictures obtained were used for counting. The total number
of cells and number of cells with aggregates were counted using Image J software and
verified manually. A minimum of 200 cells per biological repeat were counted. The
percentage of cells containing aggregates was calculated as the ratio of the number of
cells with aggregates to the total number of cells.
Examination of mitochondria
The MitoLoc plasmid (pMitoLoc) was purchased from Addgene. pMitoLoc
contained two fluorescently tagged proteins that both localized to the mitochondria - GFP
fused to the fungal mitochondrial localization signal of the F0-ATPase subunit 9
(preSu9), a mitochondrial membrane potential independent signal and mCherry protein
fused to the N-terminal localization sequence of cytochrome C oxidase 4 (preCOX4),
imported into mitochondria proportional to the membrane potential. Expression of
plasmids was achieved by transforming the plasmid into yeast strains and plating on agar
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plates containing the antibiotic nourseothricin.82 Since SNCA, tagged with a YFP,
overlapped with the GFP signal of pMitoLoc, we re-engineered the plasmid to replace
preSu9-GFP with preSu9-teal fluorescent protein (preSu9-TFP). First, we amplified the
TFP sequence by PCR with an overhang sequence of the GFP upstream region in the
pMitoLoc. The downstream region of GFP was also amplified by PCR with part of the
overhang sequence of mTFP. The two amplified products were further merged by PCR.
The pMitoLoc and the final PCR product were digested and ligated, resulting in
replacement of preSu9-GFP with preSu9-TFP. This enabled us to visualize SNCA
simultaneously with the mitochondrial structure and membrane potential - SNCA in
yellow, all mitochondria in teal, and healthy mitochondria in red. pMitoLoc was
transformed into the two strains - the vector (pRS303-GAL) and α-syn. Mating was then
performed with the strain containing GAL3A368V. Diploid yeast strains were induced in
galactose and glycerol-ethanol for 6 and 18 h, at which point microscope images were
captured. For Aim 3, the suppressor and vector plasmids were transformed into the α-syn
containing pMitoLoc. Merging of mitochondrial images were performed using ImageJ
software.
Quantification of viable and respiratory-competent cells
Diploid cells containing GAL3A368V and a-syn or vector were precultured in
medium containing 2% glucose overnight. Cultures with an OD600 of 8–14 were washed
twice with water and transferred to galactose and glycerol-ethanol conditions beginning
at an OD600 of 1.0. The cells were induced for 6 and 18 h. OD600 was measured and
recorded at the two time points, and 107 cells were diluted to a total volume of 1 mL.
Next, 100 µL of the diluted culture was isolated and mixed with 900 µL distilled water.
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Of this mixture, 10 µL was diluted with 990 µL water. For strains containing a-syn, 100
µL of the mixture was plated onto YPD and YPGE agar plates. Of the remaining mixture,
100 µL was diluted in 900 µL water. For strains with and without a-syn, 100 µL of this
final mixture was plated onto both YPD and YPGE agar plates. Thus, for all strains, we
plated a 10-5 dilution of the original culture, and for a-syn strains, in addition to a 10-5
dilution, we also plated a 10-4 dilution of the original culture. The a-syn strain was toxic
under glycerol-ethanol growth conditions; therefore, we used two dilution factors for asyn strains as we expected that a single digit colony count may give erroneous results.
Including a 10-4 dilution for a-syn strains enabled corroboration of the colony counts
recorded at the 10-5 dilution. After plating, the agar plates were incubated in a stationary
incubator at 30 °C for 3 d for YPD and 4 d for YPGE. Single colonies were counted by
visualization, and numbers were recorded. The number of colonies in YPD plates
represented cells that were viable, and the number of colonies in YPGE plates
represented cells that were respiratory-competent. For a-syn, when deciding whether to
use the counts from the 10-4 or 10-5 dilutions, we chose the one nearest to 100. This
colony count was then multiplied by the dilution factor, and statistical analyses was
performed using the final derived number.
Reactive oxygen species quantification
Diploid yeast cells containing a-syn and GAL3A368V (1 × 107 cells) were harvested
and centrifuged at 3600 rpm for 5 min after induction in galactose and glycerol-ethanol at
3, 6, and 18 h. ROS was measured using dihydroethidium (DHE),83 which was dissolved
in 500 µL of selective medium, added to the centrifuged cells, and incubated at room
temperature (23 + 2 °C) for 20 min in the dark. Cells were then centrifuged and washed
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twice with phosphate-buffered saline, and 160 µL of cells was added to black flatbottomed CoStar plates. Using a plate reader (Fisher Scientific, Ontario, Canada), the
density of the cells was measured at an OD600, and the absorbance was measured at lex =
485 nm and lem = 620 nm.84 The amount of ROS was calculated as the ratio of the
measured absorbance to OD600. The same volume of cell solution (3 µl) was used for
microscopic imaging in the Tx Red channel for visual analysis and qualitative assessment
of ROS.
Split green fluorescent protein system and oligomer engineering
DNA was prepared by digesting pRS416-GAL-ccdB-DsRed and pRS426-GALccdB-DsRed with HindIII and SlaI (or XhoI), removing the Ds Red tag and purifying the
vector. Forward and reverse primers for GFP11 were diluted to 100 µM and then further
to 1 µM. Next, 50 µL of forward and reverse primers were combined and placed in
boiling water for 10 min. The mixture was then allowed to cool completely to room
temperature for 1 h to allow annealing, 1 µL of the mixture was then diluted 10-fold, and
DNA ligation was performed. The ligation mixture had a total volume of 10 µL,
including 1 µL T4 ligase, 1 µL oligomer mixture (obtained previously), 1 µL T4 ligase
buffer, and 100–150 ng of digested linearized pRS416-Gal-ccdB or pRS426-Gal-ccdB.
This mixture was then transformed into T1K Escherichia coli bacteria and plated on
lysogeny broth agar plates containing carbenicillin. DNA was extracted from the bacterial
cells and confirmed by restriction digestion. An LR reaction was then performed to
individually insert the entry clones, SNCA, TOM6, and CIT1, into the destination vectors
of pRS416-GAL-ccdb-GFP11 and pRS426-GAL-ccdb-GFP11. The plasmid constructs
were confirmed at each step by restriction digestion and sequencing. Subsequently, the
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gateway vector was transformed into W303 MATa yeast integrated with p404-MTS
mCherry plasmid. The W303 MATa yeast strain containing GAL3A368V was mated with
the W303 MATa yeast strain containing p404-MTS-mCherry and SNCA. Since we did not
observe a green color with any of the three strains, we further examined the genetic code
of the plasmids. We noticed the presence of a stop codon in the reading frame of both
plasmid constructs that may have prevented the transcription of GFP11. We also noticed a
glycine-rich coding sequence between the gene and GFP11 that may have caused hairpin
formation. To remove the stop codon and glycine sequences, we performed Yeast Gap
Repair.85 First, PCR was performed using primers (Table 3) to synthesize the gene and
GFP11 while removing the intervening stop codon and glycine. Second, pRS416GALSNCA-GFP11 and pRS416GAL-CIT1-GFP11 were cut using HindIII enzyme, whereas
pRS416GAL-TOM6 GFP11 was cut using EcoRI enzyme. The cut plasmid was then
purified, and 400 ng of purified plasmids was mixed with 100 ng of PCR product; using a
one-step yeast transformation, this mixture was transformed into W303 MATa yeast that
had an integrated p404-MTS mCherry plasmid. Using the PCR product as template, the
yeast repairs the gap in the cut plasmid construct. The final plasmid product contained the
gene and GFP11, without the intervening stop codon and glycine sequences. The construct
was confirmed by restriction digestion, however, still required confirmation via
sequencing.
Human gene plasmid library and transformation into yeast
The Ju and Zhong laboratory generated a human gene library containing 14,827
sequence-verified individual human gene open reading frames (ORFs) (corresponding to
12,890 human genes) cloned into the destination vector pRS416GAL-ccdB (URA
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marker) in the W303 MATa yeast that contained an integrated IntTox SNCA (Table 1).
Plasmid DNA in the destination vector was stored frozen at -80 °C. A high-throughput
yeast transformation protocol86 was used to transform all the plasmid DNA. Transformed
yeast were saved as glycerol stocks and stored at -80 °C.
High-throughput screening
IntTox a-syn strain containing the human genes and strain containing GAL3A368V
were grown separately in selective glucose media overnight in 96-well plates. After
overnight growth, we used pins to cross the two strains in YPD media and grew the yeast
overnight. The grown culture was transferred using pins to a triple selective glucose
media and grown for 48 h. The culture was then spotted onto triple selective glucose and
glycerol-ethanol agar plates using the bench-top RoToR HDA robot (Singer Instruments,
Roadwater, UK). The robot spots four times for each well; thus, in the agar plate there
were a total of 384 spots. The agar plates were incubated in 30 °C for 2 d (for glucose
plates) and 5 d (for glycerol-ethanol plates) when the images were taken using a Canon
EOS 200D camera (Peschiera Borromeo (Mi), Italy).
Confirmation of genetic hits
Four types of scoring by visual examination of the agar plates were used: trace,
mild, moderate, and strong. The original human gene plasmid of the hits was revived
from the bacterial glycerol stock. The bacteria were grown in lysogeny broth with
carbenicillin and isolated using a plate miniprep technique (GenScript 96-well Plasmid
Miniprep Kit, New Jersey, USA). Next, 1.3 mL medium containing antibiotics was added
to 96-well plates. Bacteria were inoculated in the medium using pins to transfer the
glycerol stock into the new medium. The plates were covered with adhesive tape and
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grown overnight at 37 °C in a shaking incubator until an OD600 between 1–4 was
reached. The cells were then harvested by centrifugation at 2500 rpm for 10 min, and 250
µL of resuspension solution with RNase A was added to each well, followed by vigorous
vortexing. Next, 250 µL lysis solution was added to each well and thoroughly mixed, and
250 µL neutralization solution was then added. The plates were inverted multiple times
until a clear precipitate was formed. The plates were centrifuged, the supernatants were
transferred to new 96-well filter plates, and the plates were centrifuged again. Filtered
lysates were then transferred to a binding plate and centrifuged at 2500 rpm for 10 min.
The flow-through was then placed on a new deep-well plate, and 500 µL of wash solution
with ethanol was added. The samples were then centrifuged to remove residual wash
solution. The binding plate was placed on top of the collection plate and 50 µL elution
solution was added. After incubation at room temperature for 2 min, the plate was
centrifuged at 2500 rpm for 5 min. Each plasmid containing human gene clones was then
individually transformed into the IntTox a-syn W303 MATa strain using a standardized
yeast one-step transformation protocol and plated on double selective agar plates. After
allowing cells to grow at 30 °C for 4 d, the cells were isolated, grown in double selective
medium, and mated with the GAL3A368V allele from the opposite mating type. The toxicity
was confirmed after individually spotting the diploid strains.
Gene ontology analysis
Gene ontology (GO) enrichment analysis was performed using the analysis tool
found at http://geneontology.org. The software that runs the analysis is called the
PANTHER Classification System, (http://www.pantherdb.org/) which is maintained up to
date with GO annotations. This is a comprehensive system that combines data from 82
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complete genomes and their phylogenetic trees. The statistical model that is used for GO
analysis is the hidden Markov models.87 Results from this analysis will provide
information on which GO terms are overrepresented or underrepresented using
annotations for that gene set. The gene IDs of the IntTox a-syn toxicity suppressors along
with the entire list of human gene clones from the library (reference list) were used for
the analysis; duplicate genes were deleted prior to analysis. Three GO aspects - molecular
function, biological process and cellular component were set for the analysis. GO terms
shared by the suppressor list were compared to the background distribution of annotation.
The closer the p value was to zero, the more significant the GO term associated with the
group of genes was determined to be. A Fischer’s exact test was used and a Bonferroni
correction for multiple testing was selected. Only results that were Bonferroni-corrected
for p < 0.05 are displayed.
Statistical analyses
The data presented in figures as bars represent means + standard errors of the
means (SE). Experiments were performed independently a minimum of three times.
Where necessary, a natural log transformation was performed to correct for violation of
the assumption of constant variance between groups. For analysis including different time
points, interactions between genes and times were assessed first before measuring
differences between genes and controls. The differences between a-syn and controls
were assessed by one-way analysis of variance (ANOVA), two-way ANOVA, repeated
measure ANOVA, or Type III tests of fixed effects. To compare the suppressors of a-syn
with the vector, Dunnett’s test was performed. Results with p values < 0.05 were
considered significant. Analyses were performed using SAS (v. 9.4) software.
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Table 1. Yeast strains
Strain

Genotype

Reference

W303

MATa can1−100 his3−11,15 leu2−3,112
trp1−1 ura3−1 ade2−1

W303

MATa can1−100 his3−11,15 leu2−3,112
trp1−1 ura3−1 ade2−1

NoTox a-syn

α–syn-WT, MATa can1−100 his3−11,15

(1 copy of a-syn)

leu2−3,112 trp1−1 ura3−1 ade2−1

This study

pRS303-GAL-αSynWT-YFP
IntTox a-syn

α–syn-WT, MATa can1−100 his3−11,15

(4–5 copies of a-

leu2−3,112 trp1−1 ura3−1 ade2−1

syn)

pRS303-GAL-αSynWT-YFP pRS304-

42

GAL-αSynWT-YFP
HiTox a-syn

α–syn-WT, MATa can1−100 his3−11,15

(> 6 copies of a-

leu2−3,112 trp1−1 ura3−1 ade2−1

syn)

pRS304-GAL-αSynWT-GFP pRS306-GAL

42

-αSynWT-GFP
1X FUS

FUS-WT, MATa can1−100 his3−11,15

89

leu2−3,112 trp1−1 ura3−1 ade2−1
pRS303-GAL-FUSWT
2X TDP-43

TDP-43-WT, MATa can1−100 his3−11,15

88

leu2−3,112 trp1−1 ura3−1 pdr1::Kan,
pdr3::Kan pRS303-GAL-TDP-43-GFP
pRS304-GAL-TDP-43-GFP
HTT103Q

HTT103Q, MATa can1−100 his3−11,15
leu2−3,112 trp1−1 ura3−1 ade2−1
pRS303-GAL-FLAG-HTT103Q-EYFP
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Table 2. Plasmids
Plasmid

Reference

pRS303-GAL1-ccdB (HIS3)

89

pRS415-GPD-ccdB (LEU2)

This study

pRS415-GPD-GAL3 (LEU2)

This study

pRS415-GPD-GAL4 (LEU2)

This study

pRS415-GPD-GAL3-A368V (LEU2)

This study

pRS415-GPD-GAL3-F237Y (LEU2)

This study

pRS415-GPD-GAL3-S509P (LEU2)

This study

pRS415-GPD-GAL3-A368V- F237Y (LEU2)

This study

pRS415-GPD-GAL3-F237Y- S509P (LEU2)

This study

pRS415-GPD-GAL3-S509P-A368V (LEU2)

This study

pRS415-GPD-GAL3-S509P-A368V-F237Y (LEU2)

This study

pRS303-LacZ (HIS3)

Addgene

pRS416-GAL1-1433b (URA3)

This study

pRS416-GAL1-1433q (URA3)

This study

pRS416-GAL1-1433g (URA3)

This study

pRS416-GAL1-1433z (URA3)

This study

pRS416-GAL1-1433s (URA3)

This study

pRS416-GAL1-1433h (URA3)

This study

pRS416-GAL1-GLRX1 (URA3)

This study

pRS416-GAL1-TM39B (URA3)

This study

pMitoLoc-preCOX4-mCherry & preSU9-GFP

Addgene

pMitoLoc-preCOX4-mCherry & preSU9-TFP

This study

p404-Grx5-GFP1-10

99

p404-MTS-mCherry- GFP1-10

99

pRS416-GAL1-ccdB-DsRed (URA3)

This study

pRS416-GAL1-GFP11-SNCA (URA3)

This study

pRS416-GAL1- GFP11-TOM6 (URA3)

This study
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pRS416-GAL1- GFP11-CIT1 (URA3)

This study

pRS426-GAL1-ccdB-DsRed (URA3)

This study

pRS426-GAL1- GFP11-SNCA (URA3)

This study

pRS426-GAL1- GFP11-TOM6 (URA3)

This study

pRS426-GAL1- GFP11-CIT1 (URA3)

This study

pRS416-GAL1-ccdB- GFP11 (URA3)

This study

pRS426-GAL1-ccdB- GFP11 (URA3)

This study

pRS416-GAL1-ccdB (URA3)

This study
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Table 3. Primers
Name

Sequence (5′ à 3′)

t710a

CAAAACTAAAGGCCACACCTTTCAAGTATCCTCAATTGA
AAAATCAT

t710a_antisense

ATGATTTTTCAATTGAGGATACTTGAAAGGTGTGGCCTT
TAGTTTTG

a1103t

ATGATTTTTCAATTGAGGATACTTGAAAGGTGTGGCCTT
TAGTTTTG

a1103t_antisense

GGAAAAGTTGTCAGGTAAACTCTAGTGAACTCCTCAC

c1526t

GAACTAAAAGACGCAATTATAGTTTTGAAGCCTGCCTTG
G

c1526t_antisense

CCAAGGCAGGCTTCAAAACTATAATTGCGTCTTTTAGTT
C

Hind-GFP11-Xho F

AGCTTAGGTGGTGGTTCTGGAGGCGGTTCTATGAGAGAT
CATATGGTTTTGCATGAATATGTTAATGCTGCTGGTATTA
CTTAGC

Hind- GFP11-Xho R

TCGAGCTAAGTAATACCAGCAGCATTAACATATTCATGC
AAAACCATATGATCTCTCATAGAACCGCCTCCAGAACCA
CCACCTA

M13F

TGTAAAACGACGGCCAGT

Trp1_OutF

GGCAGCCCCGATCTAAAAGA

Trp1_OutR

AGACCGAGAAAAGGCTAGCA

Trp1_InR

TTTTCGCCCTTTGACGTTGG

Trp1_InF

ACTGAGAGTGCACCATAGATCA

Leu2_up_F

TGTGTAGAATTGCAGATTCCCT

Leu2_dn_R

TCGCATTATCCTCGGGTTCA

Leu2_up_F

TGTGTAGAATTGCAGATTCCCT

Leu2_int_up_R

CGGTGATGACGGTGAAAACC

Leu2_int_dn_F

CAACACTCAACCCTATCTCGG

Leu2_dn_R

TCGCATTATCCTCGGGTTCA
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TOM6_F

TGTTGGTGGTGGTTCTGGAG

CIT1_F

AACGGTGGTGGTTCTGGAG

SNCA_F

CTACGGTGGTGGTTCTGGAG
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III AIM 1: TO DEVELOP A METHOD OF GENE OVEREXPRESSION UNDER
NON-GALACTOSE CONDITIONS USING GAL3 ALLELES

Rationale
Yeast genetic screening has identified key biological pathways of many
neurodegenerative disease-related genes including SNCA,42,64,88 FUS,89 and HTT.64,90
SNCA mutations cause Parkinson’s disease, FUS mutations cause amyotrophic lateral
sclerosis (ALS), and mutations in HTT cause Huntington’s disease. However, all prior
screening studies have been performed under galactose-enriched growth condition,
exclusively. Furthermore, mutations in SNCA, FUS, and HTT cause mitochondrial
dysfunction, which is associated with disease pathology. Additionally, calorie restriction,
in yeast and animal models, has been shown to delay neurodegeneration.91,92 Autophagy,
a mechanism of recycling obsolete cellular constituents has also been widely studied in
neurodegenerative disorders. Specifically, attenuation of autophagy has been shown to
initiate development of Parkinson’s disease;93,94 while induction of autophagy delays
progression of ALS.95 As discussed previously, mitochondria can be studied under a
respiratory glycerol condition, and calorie restriction, in yeast, can be induced by
reducing the concentration of glucose in the growth medium. Further, autophagy can be
induced by depleting the medium of nitrogen.96,97 We analyzed a method that would
enable the study of genes under these non-galactose conditions. As such, we sought to
test and validate a novel overexpression system that involved constitutive GAL3 alleles
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that can induce GAL1 promoter in non-galactose conditions.75 These alleles were
integrated into a haploid yeast strain where the WT GAL3 was knocked down.. Since our
laboratory previously designed a diploid screening method,98 here we determined if the
GAL3 alleles were capable of inducing the GAL1 promoter in diploid yeast strains
without the deletion of two WT GAL3 genes.
Experimental design
GAL1 promoter and GAL3 alleles. We chose one intermediate strength and two strong
GAL3 alleles from the previous publication.75 Three mutations in the GAL3 gene (F237Y,
A368V, and S509P) were generated by site-specific mutagenesis using the pRS415-GPD
vector (LEU marker) and transformed into the WT yeast strain W303 MATa. We also
generated double- and triple-combination mutants (F237Y+A368V, F237+S509P,
A368V+S509P, and F237+A368V+S509P).
b-galactosidase assay. We used b-galactosidase assays to quantify the induction of the

GAL1 promoter under 2% glucose, 2% galactose, 3% glycerol with 1% ethanol, 2%
raffinose, calorie restriction (0.5% and 0.1% glucose), and nitrogen starvation (2%
raffinose and 2% glucose) conditions. b-galactosidase, a widely used reporter gene,
hydrolyzes o-nitrophenyl-b-D-galactopyranoside to o-nitrophenol and galactose, resulting
in a yellow color. The intensity of the yellow color was determined by measuring the
A420. An LR reaction was performed to synthesize the pRS303-LacZ plasmid. We then
performed a high efficiency yeast transformation to integrate the pRS303-LacZ plasmid
(HIS marker) into the WT yeast strain W303 MATa.
Mating strategy to perform b-galactosidase assays. We grew GAL3 alleles (MATa) and
b-galactosidase (MATa) together in YPD agar plate (Figure 2). We then transferred the
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Figure 2. Schematic representation of the mating strategy used in this study.
Mating of the b-galactosidase gene under the GAL1 promoter and the GAL3 alleles to
measure b-galactosidase activity. We used three GAL3 alleles (GAL3F237Y, GAL3A368V and
GAL3S509P) or their combinations for the experiments in Aim 1. The b-galactosidase gene
was integrated into the haploid MATa yeast strain chromosome, whereas the GAL3
alleles were transformed into the haploid opposite mating type MATa yeast strain using a
constitutive promoter, pRS415-GPD (Table 2). Single colonies of two haploid yeast
(W303 MATa containing b-galactosidase enzyme and W303 MATa containing GAL3
alleles) were crossed in YPD agar plates and allowed to grow overnight. The yeast patch
from the crossed area was picked and streaked on double selective agar plates and
incubated for 2–3 days to isolate a single colony. The resulting diploid yeast contained
both the b-galactosidase gene and the GAL3 alleles.
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cells to double-selection 2% glucose medium and grew them overnight. The cells were
then washed and transferred to double selective medium containing different carbon
sources beginning at an OD600 of 0.1. The diploid yeast strains were permitted to grow to
mid-log phase, at which point the experiment was conducted.
Results
1.1: To develop and test a method of gene overexpression under non-galactose
conditions
GAL3 alleles induce the GAL1 promoter under non-galactose conditions in the
absence of glucose. Figure 3 shows the results of b-galactosidase assays for the control,
WT GAL3, and GAL3 alleles - GAL3F237Y, GAL3A368V, and GAL3S509P. b-galactosidase is
under the control of the GAL1 promoter; thus, higher the enzyme activity results in higher
promoter induction. Glucose served as the negative control, while galactose as the
positive control. GAL3F237Y, GAL3A368V and GAL3S509P exhibited significantly higher
induction under glycerol-ethanol compared to the vector control (all p < 0.0001). For the
spotting assays, we initially analyzed the genes in a glycerol-rich growth condition and
observed that the cells expressing a-syn exhibited growth only after five days of
incubation. Hence, we supplemented the media with 1% ethanol to aid the cells in more
rapid growth. Only GAL3S509P exhibited significantly (p = 0.008) higher induction under
nitrogen starvation compared to the vector control. However, under calorie restriction
conditions, none of the alleles showed significant induction when compared to the
control. Since all three alleles exhibited significant induction in the glycerol-ethanol
condition, we hypothesized that the combination of allele mutants will elicit a more
dramatic induction of the promoter.
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Figure 3. GAL3F237Y, GAL3A368V and GAL3S509P induce GAL1 promoter under
glycerol-ethanol.
Single diploid yeast colonies containing both the b-galactosidase enzyme (W303 MATα
strain) and GAL3 alleles (W303 MATa strain) were grown overnight in double selective
2% glucose media. The pre-culture (OD600 of 8–14) was washed twice with distilled
water and inoculated into media lacking histidine (gene) and leucine (GAL3 vector)
beginning at an OD600 of 0.1. Media consisted of 2% glucose (negative control), 2%
galactose (positive control), 3% glycerol with 1% ethanol, nitrogen starvation containing
2% glucose, and calorie restriction containing 0.5% glucose. The culture was grown until
mid-log phase when the cells were isolated. The intensity of the yellow color was
measured at A420. b-galactosidase activity of GAL3WT, GAL3F237Y, GAL3A368V and
GAL3S509P was compared to the empty vector (pRS415-GPD) in each condition by twoway ANOVA. * p < 0.05 and hence significantly different compared to control; N.S, no
significant difference compared to control; WT, wild-type.
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Combining GAL3 alleles do not induce the GAL1 promoter under non-galactose
conditions. Interestingly, neither the double- nor the triple-combination mutants (Figure
4) induced the GAL1 promoter. Gal3p regularly transitions between the ‘open inactive’
and ‘closed active’ conformation, and the GAL3 alleles induce the ‘closed active’
conformation even under non-galactose conditions.73 However, the results of this
experiment suggest that the combination of alleles fails to induce the ‘closed active’
conformation. Hence, we performed structural analysis of the position of alleles and their
combinations in relation to the ‘transition site’ or the ‘switch region’ (Figure 5). We
found that F237 formed hydrophobic bonds and was located adjacent to the ‘switch’
region; a mutation in this position enabled transition to a ‘closed active’ conformation.
The combination of F237Y and S509P showed a mutual negating effect of the closed
conformation, likely caused by disruption of the b-sheet formation at S509. Thus, the
allele combinations likely inhibited transition to the ‘closed active’ conformation, thereby
preventing its constitutive action.

1.2: To test a gene overexpression method using neurodegenerative disease gene
models and GAL3 alleles
GAL3A368V and GAL3F237Y induce GAL1 promoter under glycerol-ethanol. We sought
to identify the strongest inducer among the three GAL3 alleles using IntTox a-syn under
glycerol-ethanol growth conditions. We chose the IntTox a-syn as this strain exhibits
toxicity when induced in galactose under haploid conditions. Hence, a phenotypic change
in glycerol-ethanol condition would be readily detectable. Here, we created a diploid
strain of IntTox a-syn and all three GAL3 alleles as our genetic screening will be
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Figure 4. Combinations of GAL3F237Y, GAL3A368V and GAL3S509P do not induce GAL1
promoter in non-galactose conditions.
Double and triple mutations of the alleles were generated using PCR as described in the
methods. Single diploid yeast colonies containing both b-galactosidase enzyme (W303
MATα strain) and GAL3 allele combinations (W303 MATa strain) were grown overnight
in double selective 2% glucose media. The pre-culture (OD600 of 8–14) was washed twice
with distilled water and inoculated into five different media lacking histidine (gene) and
leucine (GAL3 vector) starting at OD600 of 0.1: 2% glucose (negative control), 2%
galactose (positive control), 3% glycerol with 1% ethanol, nitrogen starvation containing
2% glucose, and calorie restriction containing 0.5% glucose. The culture was grown until
mid-log phase when the cells were isolated, and the assay was performed. The intensity
of the yellow color was measured at A420. b-Galactosidase activity of GAL3 allele
combinations was compared to the empty vector in each condition by two-way ANOVA.
N.S, no significant difference compared to control; WT, wild-type.
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Figure 5. Combination of GAL3F237Y and GAL3S509P fails to enable transition to
‘closed active’ Gal3p conformation.
(A) Position of the F237, A368 and S509 in relation to the ‘Open-Closed Pivot’ in Gal3p.
The structure on the top of the figure is the Gal3p which, in its closed conformation,
binds to the transcriptional repressor, Gal80p (gray colored structure in the bottom of the
figure). A368 is located at the transition site, which is the region where the galactose
binds and the conformation switches from ‘open inactive’ to ‘closed active’. (B) F237
forms hydrophobic bonds and is located adjacent to the ‘Switch’ region; a mutation in
this position causes transition to a closed conformation. A mutation in S509 disrupts the
adjacent β-sheet and initiates a closed conformation. However, the combination of F237
and S509 fails to enable the transition, likely due to the mutual cancelling effect caused
by disruption of the hydrophobic bonds and the β-sheet.
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performed in diploid conditions. The diploid strain was plated onto double selective
glucose (negative control), galactose (positive control) and glycerol-ethanol agar plates.
Two primary findings were observed (Figure 6). First, the IntTox a-syn was no longer
toxic under galactose condition. The only difference between previous IntTox a-syn
studies showing toxicity in galactose and our study is that previously, IntTox a-syn was
tested in haploid state while our study was performed in diploid state. Second, GAL3F237Y
and GAL3A368V induced IntTox a-syn under glycerol-ethanol condition and elicited
toxicity. Alternatively, GAL3S509P did not cause toxicity to IntTox a-syn although we saw
significant induction of the GAL1 promoter in the b-galactosidase assay (Figure 3). As
expected, GAL3WT and the empty vector did not induce the gene, corroborating the
findings of the b-galactosidase assay. Taken together the results from the spotting and bgalactosidase assays suggest that both GAL3A368V and GAL3F237Y induced the GAL1
promoter in glycerol-ethanol. Among the two, we chose GAL3A368V for the next
experiments.
GAL3A368V does not induce toxicity of neurodegenerative disease-genes in the presence
of glucose. We next wanted to determine if GAL3A368V effectively induces genes in nongalactose conditions other than glycerol, and if so, whether it causes toxicity. Four
neurodegenerative disease-related genes, SNCA (IntTox and HiTox), FUS, TDP-43, and
HTT103Q were chosen, all of which have been shown to cause cellular toxicity under
galactose condition. We generated a diploid yeast containing the genes and GAL3A368V
and plated the cells under double selective nitrogen starvation and calorie restriction
conditions. Nitrogen starvation conditions (activate autophagy) lacks ammonium sulfate
and contains 2% glucose in the media; whereas the calorie restriction condition (delays
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Figure 6. GAL3A368V and GAL3F237Y induce toxicity of IntTox a-synuclein under
glycerol-ethanol.
Single diploid yeast colonies containing empty vector (pRS303-GAL) or IntTox a-syn
(W303 MATa strain) and empty vector or GAL3 alleles (W303 MATα strain) were grown
overnight in double selective 2% glucose media lacking histidine (gene) and leucine
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(GAL3 vector). The culture was washed twice with distilled water and diluted to an OD600
of 1.0 and was spotted (left-most column). The diluted culture was further serially diluted
10-fold and spotted four times; the dilution was repeated until the last column on the
right. The dilution is indicated by the tapering triangle bar on the top. Cells were then
spotted onto solid double selective agar plates containing 2% glucose (negative control),
2% galactose (positive control), or 3% glycerol and 1% ethanol, and incubated for 2–5
days.
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neurodegeneration) has a reduced media glucose content of 0.5%. Under both conditions
with all four genes, no toxicity was observed (Figure 7).

1.3: To assess the toxicity, aggregate formation and expression level of IntTox and
HiTox a-synuclein under non-galactose conditions using integrated GAL3A368V allele.
GAL3A368V induces the GAL1 promoter in the presence of 0.1% glucose and raffinose.
We integrated the GAL3A368V allele into the yeast genome and performed b-galactosidase
assays. We chose conditions that had not been tested previously. In the calorie restriction
condition, since 0.5% glucose did not allow for GAL1 promoter induction, we now
reduced the amount of glucose to 0.1%. In addition, we tested raffinose and nitrogen
starvation. Raffinose is an alternate carbon source that undergoes partial oxidative
phosphorylation. GAL3A368V significantly increased b-galactosidase activity under calorie
restriction (p = 0.01), raffinose (p < 0.0001), and nitrogen starvation (p < 0.0001)
compared to the vector (Figure 8). Thus, we concluded that GAL3A368V can induce GAL1
promoter in non-galactose conditions provided the glucose content is relatively low.
IntTox and HiTox a-syn overexpression cause toxicity under non-galactose conditions.
Since GAL1 promoter induction was observed in the above conditions, we next tested the
IntTox and HiTox a-syn cellular phenotypes in these conditions. Glucose served as the
negative control and galactose, the positive control (Figure 9). Neither IntTox nor HiTox
a-syn induced toxicity under calorie restriction condition. We know that GAL1 promoter
is induced in this condition (Figure 8). Both IntTox and HiTox a-syn showed toxicity
under raffinose and nitrogen starvation. The addition of nitrogen starvation to raffinose
caused suppression of IntTox a-syn-induced toxicity. Of these findings, the most
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Figure 7. GAL3A368V does not induce toxicity of neurodegenerative disease-related
genes in the presence of glucose.
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Single diploid yeast colonies containing both empty vector (pRS303-GAL), IntTox and
HiTox a-syn, FUS, TDP-43 or HTT103Q (W303 MATa strain) and empty vector
(pRS415-GPD) or GAL3 alleles (W303 MATα strain) were grown overnight in double
selective 2% glucose media. The culture was washed twice with distilled water and
diluted to an OD600 of 1.0 and was spotted (left-most column). The diluted culture was
further serially diluted 10-fold and spotted four times; the dilution was repeated until the
last column on the right. The dilution is indicated by the tapering triangle bar on the top.
Cells were then spotted onto solid double selective agar plates containing 2% glucose
(negative control), 2% galactose (positive control), nitrogen starvation (2% glucose) or
calorie restriction (0.5% glucose) and incubated for 2–3 days.
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Figure 8. GAL3A368V induces the GAL1 promoter under calorie restriction and
nitrogen starvation conditions.
GAL3A368V was integrated into the yeast genome using a high efficiency yeast
transformation protocol. Single diploid yeast colonies containing both b-galactosidase
enzyme (W303 MATα strain) and GAL3A368V (W303 MATa strain) were grown overnight
in double selective 2% glucose media. The culture was washed twice with distilled water
and inoculated into five different media lacking histidine (gene) and leucine (GAL3
vector) starting at OD600 0.1: 2% glucose (negative control), 2% galactose (positive
control), calorie restriction (0.1% glucose), 2% raffinose, and nitrogen starvation (2%
raffinose). The culture was grown until mid-log phase when the cells were isolated, at
which point the assay was performed. The intensity of the yellow color was measured at
A420. b-galactosidase activity of GAL3A368V was compared to the empty vector in each
condition by two-way ANOVA. * p < 0.05 and, hence, significantly different compared
to the control. N.S, no significant difference compared to control.
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Figure 9. IntTox and HiTox a-synuclein overexpression cause toxicity under nongalactose conditions.
Single diploid yeast colonies containing both empty vector (pRS303-GAL), IntTox asyn, or HiTox a-syn (W303 MATa strain) and empty vector (pRS415-GPD) or GAL3A368V
(W303 MATα strain) were grown overnight in double selective 2% glucose media. The
culture was washed twice with distilled water and diluted to an OD600 of 1.0 and was
spotted (left-most column). The diluted culture was further serially diluted 10-fold and
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spotted four times; the dilution was repeated until the last column on the right. The
dilution is indicated by the tapering triangle bar on the top. Cells were then spotted onto
solid double selective agar plates containing 2% glucose (negative control), 2% galactose
(positive control), calorie restriction (0.1% glucose), 2% raffinose, and nitrogen
starvation (2% raffinose), and incubated for 2–7 days.
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interesting is the absence of toxicity in HiTox a-syn cultures in calorie restriction
condition, while toxicity was present in IntTox a-syn cultures containing raffinose, as
these findings are in stark contrast to those previously observed for galactose.65 Hence,
this study highlights the necessity of studying a-syn in non-galactose conditions and
validates the use of GAL3A368V performing the same.
IntTox and HiTox a-syn toxicity do not correlate with the presence of aggregates
under non-galactose conditions. Toxicity of IntTox and HiTox a-syn often correlates
with the presence of aggregates in yeast.65 Since we observed toxicity of the two strains
in the spotting assay, we next sought to examine a-syn aggregates under the same
conditions. Under calorie restriction, no IntTox a-syn aggregates were observed,
however, those of HiTox a-syn were evident (Figure 10 and 11). Under raffinose and
nitrogen starvation conditions, we saw similar patterns with aggregates only being
formed by HiTox a-syn, not IntTox a-syn (Figure 10 and 11). When comparing the
results of the spotting assay and microscopic aggregates, two interesting findings become
apparent. First, although IntTox a-syn was toxic under raffinose conditions, no
aggregates were formed. Second, HiTox a-syn was not toxic under calorie restriction but
aggregates were formed. Thus, non-galactose conditions serve to define a new paradigm
shift were toxicity produced by a-syn does not necessarily correlate with the presence of
aggregates. The next logical question was whether the expression levels of a-syn under
non-galactose conditions are responsible for the observed differences in toxicity and
aggregation.
Although verification of expression levels across growth conditions require
further experimental repeats, IntTox a-syn did not seem to exhibit different expression
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levels in the non-galactose growth conditions compared to that in galactose. HiTox a-syn
seemed to show higher expression levels in calorie restriction, raffinose and nitrogen
starvation conditions (Figure 12). In either situation, the results do not explain the
increased toxicity of IntTox a-syn in raffinose conditions nor the reduced toxicity of
HiTox a-syn in calorie restriction conditions. It, therefore, appears that the toxicity is not
mediated by protein expression levels.
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Figure 10. IntTox a-synuclein does not form aggregates under non-galactose
conditions.
Single diploid yeast colonies containing both IntTox a-syn (W303 MATa strain) and
GAL3A368V (W303 MATα strain) were grown overnight in double selective 2% glucose
media. The culture was washed twice with distilled water and diluted to an OD600 of 1.0
and was grown in double selective media of four types: 2% galactose, calorie restriction
(0.1% glucose), raffinose and nitrogen starvation (2% raffinose), and induced for 4, 6 and
8 h. At each time point, the cells were isolated and 3 µL of suspension was placed on a
glass slide and viewed under the bright field and YFP channel. Bar: 5 µm. BF, bright
field.
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Figure 11. HiTox a-synuclein forms aggregates under non-galactose conditions.
Single diploid yeast colonies containing both HiTox a-syn (W303 MATa strain) and
GAL3A368V (W303 MATα strain) were grown overnight in double selective 2% glucose
media. The culture was washed twice with distilled water and diluted to an OD600 of 1.0
and was grown in four different types of double selective media: 2% galactose, calorie
restriction (0.1% glucose), raffinose and nitrogen starvation (2% raffinose), and induced
for 4, 6 and 8 h. At each time point, the cells were isolated and 3 µL of suspension was
placed on a glass slide and viewed under the BF and YFP channels. Scale bar: 5 µm. BF,
bright field.
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Figure 12. HiTox a-synuclein expression increases while IntTox a-synuclein
expression is unaffected under non-galactose conditions.
Single diploid yeast colonies containing both IntTox a-syn, or HiTox a-syn (W303
MATa strain) and empty vector (pRS415-GPD) or GAL3A368V (W303 MATα strain) were
grown overnight in double selective 2% glucose media. The culture was washed twice
with distilled water and diluted to an OD600 of 1.0 and was grown in four different types
of double selective media: 2% galactose, calorie restriction (0.1% glucose), raffinose and
nitrogen starvation (2% raffinose). The cultures were then induced for 6 h after which
point the protein was extracted. SNCA encoding IntTox a-syn, or HiTox a-syn were
tagged with YFP and, hence, an antibody against GFP was used. PGK1 was used as the
loading control protein. (A) shows the blotting images and (B) shows quantification of
the bands. Image quantification was performed using ImageJ. The experiment was
repeated twice, and the bar graphs represent mean + SE. Protein expression in galactose
condition served as reference values.
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IV. AIM 2: TO EXAMINE THE ROLE OF MITOCHONDRIA IN a-SYNUCLEIN
TOXICITY UNDER GLYCEROL-ETHANOL
Rationale
When a-syn was induced under non-galactose conditions, variations were
observed in the toxicity levels, presence of aggregates and protein expression. For this
study, we focused on the glycerol-ethanol condition, which is a non-fermentable carbon
source for yeast and thus requires a fully functional mitochondria for survival. We know
that mitochondrial dysfunction causes Parkinson’s disease, and a-syn affects the
mitochondria by inhibiting complex I activity and causing mitochondrial fragmentation.
Since we observed higher toxicity of a-syn in glycerol-ethanol compared to galactose, we
sought to better understand the underlying mechanisms related to this new phenotype.
Since mitochondria appears to be vital in glycerol metabolism, we focused on studying
the respiratory competency of the cells, mitochondrial structure and membrane potential,
as well as ROS production.
Experimental design
Spotting assay. The strains that were used include NoTox a-syn (1 copy of SNCA),
IntTox a-syn (4–5 copies of SNCA), and HiTox a-syn (> 6 copies of SNCA). We also
assessed the toxicity of two ALS disease-associated genes: FUS and TDP-43. For this
Aim, SNCA, FUS, and TDP-43 were transformed into the W303 MATa of yeast (Table
1), and GAL3A368V was transformed into the opposite mating type W303 MATa. Without
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mating, we also spotted the genes on galactose and glycerol-ethanol plates under haploid
conditions (without GAL3A368V).
Measurement of aggregates and examination of mitochondria. We used IntTox a-syn
strain tagged with YFP for microscopic examination of aggregates; while pMitoLoc was
used to simultaneously examine total and healthy mitochondria. For both measurements,
diploid yeast strains containing IntTox a-syn and GAL3A368V were precultured in 2%
glucose medium overnight. Cultures with an OD600 between 8–14 were then washed and
resuspended in selective galactose or glycerol-ethanol medium. The starting OD600 was
1.0 and the suspended medium was incubated for 3–18 h. Aggregates were visualized
with the YFP channel and mitochondria were visualized with the CFP and Tx Red
channels.
Measurement of ROS. After induction for 3, 6 and 18 h, cells were isolated and
incubated with DHE for 20 min. The amount of red fluorescence was directly
proportional to the amount of ROS produced. Diploid yeast strains containing IntTox asyn and GAL3A368V were used.
Mitochondrial targeting of a-synuclein. We used a split GFP system for this
experiment.99 SNCA was cloned with the 11th b-strand of GFP (GFP11). If SNCA (cloned
to GFP11) reconstitutes with GFP1-10, which contain mitochondrial targeting sequences,
we would expect to see green fluorescence emitted from the reconstituted GFP.
Results
2.1: To test the toxicity and aggregation of IntTox a-synuclein under glycerolethanol
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IntTox a-syn is toxic under glycerol-ethanol but not under galactose condition with
similar expression. A single copy of SNCA (NoTox a-syn), 4–5 copies of SNCA (IntTox
a-syn), and > 6 copies of SNCA (HiTox a-syn), FUS and TDP-43 (Table 1) were
transformed into the MATa yeast strain W303; while GAL3A368V, was transformed into the
MATa yeast strain. The toxicity phenotypes of the a-syn diploid strains were detected by
spotting assays under galactose and glycerol-ethanol agar plates. NoTox a-syn did not
exhibit toxicity under either condition (Figure 13). Alternatively, IntTox a-syn was toxic
under the glycerol-ethanol condition but not toxic under the galactose condition; while
HiTox a-syn, FUS and TDP-43 were toxic under both conditions.
We also tested all genes under haploid conditions without GAL3A368V to better
understand (i) if the glycerol-ethanol condition alone is toxic to the cells and (ii) if a
phenotypic difference was observable for the genes, between the haploid and diploid
strains. Results show that without GAL3A368V, no induction under glycerol-ethanol
conditions was observed (Figure 14); and no toxicity was induced by any of the genes.
Further, compared to diploid strain spotting, IntTox a-syn exhibited a unique phenotype
i.e. higher toxicity in the haploid strain. Given these two interesting phenotypes, we
decided to employ only IntTox a-syn in subsequent experiments.
The OD600 measurement during the induction of IntTox a-syn in liquid media
over time corroborated the findings of the spotting assay. Under the glycerol-ethanol
condition IntTox a-syn was found to be more toxic than galactose (Figure 15). As a
haploid strain, IntTox a-syn showed toxicity in galactose (blue dotted line), however, no
induction was observed and thus, no toxicity was present in the glycerol-ethanol (orange
dotted line). To further verify our findings, we wanted to examine if the expression of
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Figure 13. IntTox a-synuclein is toxic under glycerol-ethanol but not under
galactose.
Single diploid yeast colonies containing both empty vector (pRS303-GAL), NoTox asyn, IntTox a-syn, HiTox a-syn, FUS, or TDP-43 (W303 MATa strain) and empty vector
(pRS415-GPD) or GAL3 alleles (W303 MATα strain) were grown overnight in double
selective 2% glucose media. The culture was washed twice with distilled water and
diluted to an OD600 of 1.0 and was spotted (left-most column). The diluted culture was
further serially diluted 5-fold and spotted four times; the dilution was repeated until the
last column on the right. The dilution is indicated by the tapering triangle bar on the top.
Cells were then spotted onto solid double selective agar plates containing 2% glucose
(negative control), 2% galactose (positive control), or 3% glycerol and 1% ethanol, and
incubated for 2–5 days.
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Figure 14. IntTox a-synuclein is toxic under galactose in haploid condition.
Single haploid yeast colonies containing empty vector (pRS303-GAL), NoTox a-syn,
IntTox a-syn, HiTox a-syn, FUS, or TDP-43 (W303 MATa strain) was grown overnight
in double selective 2% glucose media. The culture was washed twice with distilled water
and diluted to an OD600 of 1.0 and was spotted (left-most column). The diluted culture
was further serially diluted 5-fold and spotted four times; the dilution was repeated until
the last column on the right. The dilution is indicated by the tapering triangle bar on the
top. Cells were then spotted onto solid double selective agar plates containing 2% glucose
(negative control), 2% galactose (positive control), or 3% glycerol and 1% ethanol, and
incubated for 2 – 5 days.

57

Figure 15. IntTox a-synuclein is toxic under glycerol-ethanol but not under
galactose in diploid yeast strains.
Three yeast strains were used: IntTox a-syn without GAL3A368V (haploid), InTox a-syn
with empty vector (pRS303-GAL) (diploid control) and IntTox a-syn with GAL3A368V
(diploid GAL3A368V). Single haploid or diploid yeast colonies were grown overnight in
double selective 2% glucose media. The culture was washed twice with distilled water
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and diluted to an OD600 of 0.1 and resuspended in selective 2% galactose (A) or 3%
glycerol with 1% ethanol (B) liquid media. The OD600 was measured at 2, 4, 6 and 18 h.
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IntTox a-syn was higher in glycerol-ethanol. IntTox a-syn protein levels were similar
under both conditions (Figure 16A, B). Thus, glycerol-ethanol increased the toxicity of
neurodegenerative disease-associated genes. However, fluctuations in protein expression
levels was not responsible for the increased toxicity of IntTox a-syn.
IntTox a-syn forms aggregates under glycerol-ethanol and not under galactose. Our
next objective was to examine the aggregate formation of IntTox a-syn in both the
conditions. IntTox a-syn was tagged with YFP and the diploid strain was induced for 4,
6, 8, and 18 h. Under the galactose condition, very few aggregates of IntTox a-syn were
observed before 8 h (Figure 17A), and less than 5% of the cells (Figure 17B) contained
aggregates at 18 h. Alternatively, under the glycerol ethanol condition, the aggregates
were visible as early as 6 h and increased steadily until 18 h of induction, at which point,
approximately 55% of the cells contained aggregates and this percentage was
significantly higher than that in galactose (p = 0.0001).
We also examined the aggregates in the haploid strain and found that under
galactose condition after 18 h of induction, the proportion of cells with aggregates was
approximately 45% (Figures 18 A and B); while under the glycerol-ethanol condition,
no induction of IntTox a-syn was observed. Under galactose, the diploid control and
diploid GAL3A368V had significantly lower (both p < 0.04) number of aggregates
compared to haploid condition. There was no difference (p = 0.16) between diploid
glycerol-ethanol and haploid galactose conditions.

2.2: To determine the mechanisms of IntTox a-synuclein toxicity under glycerolethanol
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Figure 16. Protein expression levels of IntTox a-synuclein do not differ between
galactose and glycerol-ethanol conditions.
Single diploid yeast colonies containing both IntTox a-syn (W303 MATa strain) and
GAL3A368V (W303 MATα strain) were grown overnight in double selective 2% glucose
media. The culture was washed twice with distilled water and diluted to an OD600 of 1.0
and was grown in double selective 2% galactose and 3% glycerol with 1% ethanol. Cells
from cultures with an OD600 of 1.0 (1 x 107 cells) were isolated at 4, 6, 8 and 18 h of
induction and the protein was extracted. SNCA encoding IntTox a-syn was tagged with
YFP and an antibody against GFP was used. The loading control protein used was PGK1.
(A) shows the blotting images and (B) shows quantification of the bands. Image
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quantification was performed using ImageJ. The experiment was repeated three times,
and the bar graphs represent mean + SE. Protein expression at 8 h of induction in
galactose was used as the reference value. N.S., not significantly different compared to
protein levels at 8 h galactose.
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Figure 17. Aggregates of IntTox a-synuclein are elevated under glycerol-ethanol
compared to galactose.
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Single diploid yeast colonies containing both IntTox a-syn (W303 MATa strain) and
GAL3A368V (W303 MATα strain) were grown overnight in double selective 2% glucose
media. The culture was washed twice with distilled water and diluted to an OD600 of 1.0
and was grown in double selective 2% galactose and 3% glycerol with 1% ethanol media,
and induced for 4, 6, 8 and 18 h. At each time point, the cells were isolated and 3 µL of
suspension was placed on a glass slide and aggregates were viewed under the YFP
channel. Scale bar: 5 µm (A). Quantification of the aggregates (B) were performed using
ImageJ and verified by manual counting. The experiments were repeated three times and
a minimum of 200 cells were counted for each condition and timepoint. Bars represent
mean + SE. Repeated measures ANOVAs with a random subject effect was used to
compare the percentage of cells with a-syn aggregates in galactose and glycerol-ethanol
at each time points. BF, bright field. *p < 0.05 and hence, significantly different
compared to galactose. N.S., not significant.
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Figure 18. Aggregates of IntTox a-synuclein are elevated in haploid galactose and
diploid glycerol-ethanol yeast strains.
Three yeast strains were used: IntTox a-syn without GAL3A368V (haploid), InTox a-syn
with empty vector (pRS303-GAL) (diploid control) and IntTox a-syn with GAL3A368V
(diploid GAL3A368V). Single haploid or diploid yeast colonies were grown overnight in
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double selective 2% glucose media. The culture was washed twice with distilled water
and diluted to an OD600 of 1.0 and was grown in double selective 2% galactose and 3%
glycerol with 1% ethanol media and induced for 18 h. Cells were isolated and 3 µL of
suspension was placed on a glass slide. Aggregates were viewed under the YFP channel.
Scale bar: 5 µm (A). Quantification of the aggregates (B) was performed using ImageJ
and verified by manual counting. The experiments were repeated three times and a
minimum of 200 cells were counted for each condition and timepoint. Bars represent
mean + SE. Two-way ANOVA was used to compare the percentage of cells with a-syn
aggregates in galactose and glycerol-ethanol conditions. The assumption of constant
variance was violated, due to two of the groups having values of zero. Satterthwaite’s
approximation was used to adjust the degrees of freedom to account for this violation.
Natural log transformation was used for the data before analysis. Since the natural log of
zero is undefined, a value of 1 was added to all observations. All results are in terms of
natural log (response value + 1). BF, bright field; *p < 0.05; N.S., not significant.
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IntTox a-syn reduces both viability and respiratory competency only under glycerolethanol. We first sought to quantify the number of viable and respiratory-competent cells
in each condition to better understand the increased toxicity in glycerol-ethanol. The
experiment was performed as explained under Methods (Quantification of viable and
respiratory-competent cells). Respiratory competency refers to cells having fully
functional mitochondria and the capacity to grow in glycerol-ethanol condition. We
expected that IntTox a-syn would induce dysfunction of the mitochondria irrespective of
the growth condition. Since galactose is a fermentable carbon source that requires
functional mitochondria for viability, we hypothesized that under galactose, viability
would not be reduced, however, the respiratory competency would be.
Figure 19 A and B shows that the viability of the IntTox a-syn was not affected
in galactose however, it was significantly (p = 0.009 for 6 h and p = 0.04 for 18 h)
reduced in glycerol-ethanol in the presence of IntTox a-syn. Conversely to what we
expected, respiratory competency was lower but was not significantly reduced by IntTox
a-syn in galactose (Figure 19 C), however, was reduced in glycerol-ethanol (Figure 19
D). We analyzed these results for statistically significant interactions between gene and
the time required before differences were observed between IntTox a-syn and the
control; however, we did not observe any interactions, thereby ruling out potential
skewed results. Hence, we concluded that IntTox a-syn affects viability and respiratory
competency only under glycerol-ethanol.
Mitochondria show dense morphology under glycerol-ethanol and disrupted
membrane potential signal under both galactose and glycerol-ethanol in the presence
of α-syn. Using pMitoLoc, healthy mitochondria can be identified via the co-localization
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Figure 19. IntTox a-synuclein reduces the number of viable and respiratorycompetent cells only under glycerol-ethanol.
Single diploid yeast colonies containing both control (pRS303-GAL) or IntTox a-syn
(W303 MATa strain) and GAL3A368V (W303 MATα strain) were grown overnight in
double selective 2% glucose media. The culture was washed twice with distilled water
and diluted to an OD600 of 1.0 and was grown in double selective 2% galactose and 3%
glycerol with 1% ethanol media, and induced for 6 and 18 h. At an OD600 of 1.0 cells
were harvested and diluted; for a-syn strain, 100 µL each of 10-4 dilution and 10-5
dilution, and for the control strain, 100 µL of the 10-5 dilution from both medias were
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plated on YPD and YPGE agar plates to determine the numbers of viable (A) and
respiratory-competent cells (B), respectively. Agar plates were incubated for 2 – 3 days
and single colonies were counted. For a-syn strain, the dilution that provided colony
counts closer to 100 was chosen. The colony counts for both strains were multiplied by
the respective dilution factor and used for statistical analysis. Type III tests of fixed
effects were used to analyze the difference between a-syn and the control at each
timepoint. A natural log transformation was performed to correct for violation to the
assumption of constant variance between groups. * p < 0.05; Y-axis, logarithmic scale;
N.S., not significant; OD, optical density.
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of teal and mCherry; whereas unhealthy mitochondria are identified as having reduced or
no co-localization. Moreover, in unhealthy mitochondria mCherry will diffuse throughout
the cytoplasm. The lower the co-localization, the lower was the membrane potential. This
is due to the inability of preCOX4-mCherry to enter the mitochondria when the
membrane potential is lower, causing it to instead disperse throughout the cytoplasm. As
shown in Figure 20, IntTox a-syn induced the formation of dense mitochondrial
structures rather than as thread-like elongated structures under glycerol-ethanol. This may
be due to large IntTox a-syn aggregates in glycerol-ethanol and thus, the mitochondrial
structures are more closely packed together, compared to galactose condition. We also
observed the disrupted membrane potential signal, i.e. the reduced overlap of teal and red
both under galactose and glycerol-ethanol. Further mitochondrial structure specific
examination is required to confirm the results of disrupted membrane potential signal.

a-syn increases the percentage of cells that accumulate ROS under both conditions.
We examined ROS production at 3, 6, and 18 h of induction in both conditions. ROS has
been shown to increase a-syn aggregation while a-syn increases ROS production. Hence,
we hypothesized that under both conditions, increased ROS production would be
observed, however, more so under glycerol-ethanol condition since in glycerol-ethanol
oxidative phosphorylation, the major source of ROS production, would be elevated in this
condition. Further, since IntTox a-syn is more toxic in glycerol-ethanol; the toxicity may
be mediated via increased ROS production. We first performed quantitative assessment
of ROS using a plate reader. We observed that IntTox a-syn increased ROS levels at 6 h
(p = 0.04) and 18 h (p < 0.001) in galactose and at 18 h (p = 0.002) in glycerol-ethanol
compared to galactose (Figure 21). Microscopic examination did not reveal increased
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Figure 20. Mitochondria show dense morphology under glycerol-ethanol and
disrupted membrane potential signal under both galactose and glycerol-ethanol in
the presence of α-synuclein.
Single diploid yeast colonies containing both vector (pRS303-GAL) or IntTox a-syn
(W303 MATa strain) and GAL3A368V (W303 MATα strain) were grown overnight in
double selective 2% glucose media. The vector and α-syn strain were transformed with
pMitoLoc which contains two (preSU9-CFP and preCOX4-mCherry) tags with
mitochondrial targeting sequences. Teal represents all mitochondria and red represents
healthy mitochondria. The culture was washed twice with distilled water and diluted to an
OD600 of 1.0 and was grown in double selective 2% galactose and 3% glycerol with 1%
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ethanol media, and induced for 18 h. At each time point, the cells were isolated and 3 µL
of suspension was placed on a glass slide and aggregates were viewed under the YFP,
CFP and Tx Red channels. SNCA encoding α-syn was tagged with YFP. CFP images
were obtained by Z-stack. Images of mitochondria were merged using ImageJ. Scale bar:
5 µm. BF, bright field.
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Figure 21. Quantitative assessment of reactive oxygen species under galactose and
glycerol-ethanol conditions in the presence of α-synuclein.
Single diploid yeast colonies containing both vector (pRS303-GAL) or IntTox a-syn
(W303 MATa strain) and GAL3A368V (W303 MATα strain) were grown overnight in
double selective 2% glucose media. The culture was washed twice with distilled water
and diluted to an OD600 of 1.0 and was grown in double selective 2% galactose and 3%
glycerol with 1% ethanol media, and induced for 3, 6 and 18 h. Cells were incubated with
dihydroethidium (DHE) for 20 min in the dark and absorbance was measured at λex =
485 nm and λem = 620 nm. The amount of ROS generated was calculated as the ratio of
the absorbance to the OD600. Repeated measures ANOVA with a random subject effect
were run to analyze the difference between a-syn and the control. The experiment was
repeated three times and the bars represent mean + SE. * p < 0.05 and hence significantly
different compared to control. # p < 0.05 and hence significantly different compared to
galactose.
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ROS under the two conditions. However, upon closer examination many cells were
stained with red fluorescence (Figure 22 A) in both conditions. We then examined the
proportion of these bright red cells (Figure 22 B) and determined that there were more in
both conditions in the presence of IntTox a-syn (both p < 0.004) with no apparent
difference between the two conditions. The bright red fluorescent cells appeared dead
under bright field microscopy. Hence, the higher ROS that was seen with the plate reader
measurement was likely due to the higher red fluorescence emitted by the large number
of cells that accumulate ROS. Taken together these results suggest that no significant
increase in ROS production occurred, however, increased cell death due to accumulation
of ROS was observed in both conditions.
Finally, we sought to examine if IntTox a-syn localizes to the mitochondrial
matrix, thereby directly inhibiting its function under glycerol-ethanol. For this, we used a
previously validated split GFP system, where the first ten GFP b-sheets (GFP1-10) are
tagged with the mitochondrial targeting sequence and the 11th b-sheet (GFP11) is tagged
with the gene of interest, in our case, SNCA. We did not see mitochondrial targeting of asyn in either condition (Figure 23). However, we used CIT1, a mitochondrial matrix
protein, as a positive control, which also did not show targeting to the matrix. Assuming
the intervening stop codon prevented the transcription of the gene, we performed PCR
analysis and Yeast Gap Repair to remove it. We also confirmed the in-frame sequence of
SNCA in the GFP11 construct. However, we were still unable to observe targeting with the
positive control. Thus, although the construct required to perform the targeting
experiment has been created, further experimental optimizations are required before the
targeting of a-syn to mitochondrial matrix can be confirmed. Although we were unable
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to directly detect mitochondrial targeting, we did observe dense mitochondrial structures
under glycerol-ethanol and were, therefore, able to corroborate the findings of the
pMitoLOC analysis.
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Figure 22. Number of cells that accumulate ROS are elevated under galactose and
glycerol-ethanol conditions in the presence of α-synuclein.
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The same sample of cells from Figure 22 was used for microscopic imaging. Three
microliters of cells were placed on the glass slide and viewed under YFP (α-syn) and Tx
Red (ROS) channels. ROS, when generated in the cells react with DHE and emit red
color; the intensity of the red color indicates the amount of ROS. (A) ROS and α-syn in
galactose and glycerol-ethanol at 3, 6 and 18 h of induction. (B) Quantification of the
cells that accumulate ROS (bright red fluorescence in [A]) in two conditions at 18 h of
induction. Proportion of cells that accumulate ROS were calculated as the ratio of the
number of bright red fluorescent cells to the total number of cells. The experiments were
repeated three times and the bars represent mean + SE. Two-way ANOVA was used to
analyze the difference between α-syn and the control. Data had to be natural log
transformed in order to adhere to the assumption of constant variance * p < 0.05 and
hence significantly different compared to control. Scale bar: 5 µm. BF, bright field; N.S.,
not significant; ROS, reactive oxygen species.
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Figure 23. Targeting of a-synuclein to mitochondria was not successful.
SNCA (W303 MATa strain) was tagged with GFP11; this strain was also transformed
GFP1-10 with a mitochondrial targeting sequence tagged with mCherry. Single diploid
yeast colonies containing both SNCA (GFP11 tagged) and GAL3A368V (W303 MATα strain)
were grown overnight in double selective 2% glucose media. The culture was washed
twice with distilled water and diluted to an OD600 of 1.0 and grown in double selective
2% galactose and 3% glycerol with 1% ethanol media, and induced for 18 h. Cells were
isolated and 3 µL of suspension was placed on a glass slide. Cells were viewed under
GFP and Tx Red channels. Mitochondria appeared red (Tx Red channel) and a-syn, if
targeted to mitochondria, should appear green (GFP channel) due to GFP fusion. Scale
bar: 5 µm. BF, bright field.
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V. AIM 3: TO SCREEN AND CHARACTERIZE THE SUPPRESSORS OF INTTOX
a-SYNUCLEIN TOXICITY UNDER GLYCEROL-ETHANOL

Rationale
Screening of overexpressed a-syn genes in yeast under galactose conditions has
contributed to the elucidation of the pathophysiology, genetic interactions, and biological
pathways underlying Parkinson’s disease.39,42,64,65,100,101 In our study, we observed
previously unknown phenotypes of a-syn under glycerol-ethanol. However, genetic
screening to identify modifiers of a-syn has not yet been performed under glycerolethanol condition. Previous genetic screening techniques require first identifying yeast
genes that can modify toxicity, and only after identifying its human homolog can the
effects of the modifier be further analyzed. Since our lab has a collection of
approximately 15,000 human genes cloned into yeast expression vectors, we designed a
model for a human gene library and GAL3A368V, effectively bypassing the need for crossspecies comparisons and allowing for the direct screening of human gene modifiers of
IntTox a-syn toxicity under glycerol-ethanol.
Experimental design
Human gene library and genetic screening by mating. To study human genes in yeast,
our laboratory has successfully cloned 14,827 full-length sequences verified to be human
gene clones into the Gateway yeast expression vector pRS416-GAL1-ccdB. Each
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overexpressed human gene clone was transformed into the WT haploid strain W303
MATa containing a-syn. This yeast strain was mated with a strain containing GAL3A368V
(W303 MATa). The diploid yeast was grown in selective media for 48 h before plating on
glucose (negative control) and glycerol-ethanol plates (Figure 24). We did not perform
screening in galactose condition as IntTox a-syn was not toxic under diploid galactose
conditions.
Confirmation of genetic hits. Scoring of the genetic hits was performed by visually
examining the phenotypes of the yeast strain in glycerol-ethanol agar plates (Figure 25).
Four types of scoring were employed: trace, mild, moderate, and strong. We chose 184
hits and the original plasmid of these hits was revived from the bacterial glycerol stock.
The process of plasmid isolation and individual transformation into yeast are described
under Methods (Confirmation of genetic hits). Once the yeast strains were ready, the
toxicity was re-evaluated by spotting of the diploid strains. This verification step allowed
us to exclude false positives.
Results
3.1: To identify human gene suppressors of IntTox a-synuclein toxicity under
glycerol-ethanol
Unique suppressors of IntTox a-syn are identified under a glycerol-ethanol. Based on
an initial screening of 14,827 human genes, we identified 184 hits that suppressed the
toxicity of α-syn under glycerol-ethanol conditions. After confirmation, 87 hits remained.
The confirmed suppressors were compared with the list of suppressors of IntTox a-syn
toxicity under haploid galactose conditions (previously performed in our lab). Of these 87
hits, only 44 were present in galactose screening. Of the 43 hits, eight of the genes had
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Figure 24. Schematic representation of the yeast overexpression screening to
identify suppressors of IntTox a-synuclein toxicity under glycerol-ethanol.
(A) Human gene clones (14,827) were cloned into a yeast expression vector and
individually transformed into a yeast strain. The yeast strains were then stored as glycerol
stocks in individual wells of 96-well plates. (B) The human genes were transformed into
a strain containing a-syn, which were then mated with a strain of the opposite mating
type containing the GAL3A368V allele. (C) The diploid yeast strain was selected and
assessed for its ability to suppress a-syn toxicity.
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Figure 25. Sample image of spotting showing a suppressor of IntTox α-synuclein in
glycerol-ethanol agar plate.
IntTox a-syn and human gene clone were transformed into the W303 MATa strain.
GAL3A368V was transformed into the W303 MATα strain. Single colonies from both
strains were grown in 96-well plates. Each strain was transferred into a single 96-well
plate containing YPD media and grown overnight for mating. The mixture was then
transferred to another 96-well plate containing double selective 2% glucose media for
selection of diploid strains containing a-syn, human gene clone and GAL3A368V. The
culture was grown for 48 h and then spotted onto 2% glucose and 3% glycerol with 1%
ethanol agar plates. The agar plates were incubated for 3–5 days, at which point the
images were obtained. The background growth in glycerol-ethanol shows the toxic
phenotype of a-syn. The yellow box highlights a suppressor. Each diploid strain was
spotted in quadruplicate, and each of the four dots represented a single human gene clone.
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mitochondrial-related functions.
Gene ontology analysis of the hits in suppressor screening of IntTox a-syn under
glycerol-ethanol. We used 87 hits from the glycerol-ethanol screening to perform the GO
term enrichment analysis and identified groups of genes that are enriched based on
molecular function, biological process and cellular compartment (Table 4). Based on
molecular function, the analysis showed a 14.2-fold enrichment in genes with RNA
polymerase II distal enhancer sequence-specific DNA binding, followed by an 8.9-fold
enrichment with DNA-binding transcription activator activity, RNA polymerase IIspecific, and 5.1-fold enrichment of RNA polymerase II regulatory region DNA binding.
Based on biological process, the analysis showed a 22.1-fold enrichment of genes
involved in embryonic skeletal system morphogenesis, 12.0-fold enrichment of
anterior/posterior pattern specification and a 5.0-fold enrichment of positive regulation of
transcription by RNA polymerase II. A cellular component-based analysis showed 2-fold
enrichment of genes in the nucleoplasm while approximately 0.2-fold
underrepresentation of genes in the integral component of the membrane and the
organelle membrane was observed.
14-3-3 protein isotypes suppress IntTox a-syn toxicity under glycerol-ethanol
condition. Of the eight hits that had mitochondrial-related functions, four of them were
14-3-3 isotypes (Table 5). There is a total of seven 14-3-3 protein isotypes, of which our
library had six (b, q, g, z, s, and h). The one isotype we did not have was 14-3-3ε. Of the
six isotypes, four (b, q, g, and z) suppressed the toxicity of IntTox a-syn (Table 5). We
confirmed the end-read sequencing of all six 14-3-3 isotype clones.
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Table 4. Gene ontology enrichment analysis of IntTox α-synuclein suppressor hits.

GO category

# genes
in the
library

# of
hits

# of
expected
hits

Fold
enrichment

over (+)
or under
(-)
represent
ed

p value

Molecular Function
RNA polymerase
II distal enhancer
sequence-specific
DNA binding
DNA-binding
transcription
activator activity,
RNA polymerase
II-specific
RNA polymerase
II regulatory
region DNA
binding

72

7

0.49

14.15

+

0.002

310

19

2.13

8.92

+

1.3E09

374

13

2.57

5.06

+

0.005

Biological Process
Embryonic stem
cell
morphogenesis
Anterior/posterior
pattern
specification
Positive
regulation of
transcription by
RNA polymerase
II

66

10

0.45

22.06

+

6.42E07

146

12

1

11.96

+

5.18E06

819

28

5.63

4.98

+

5.95E09

Cellular Component
34
16.8
2.02

Nucleoplasm
2446
+
0.03
Integral
component of
3600
5
24.73
0.2
0.0003
membrane
Organelle
2469
3
16.96
0.18
0.02
membrane
The enrichment analysis was performed using the online tool as described under
Methods (Gene Ontology enrichment analysis). The analysis list included all genes
that were confirmed as suppressors (n = 87) of toxicity in glycerol-ethanol plates in
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the large-scale screening analysis. The reference list included the list of genes from
the human library (n = 12,890). Duplicate clones were removed prior to analysis. A
Fischer’s exact test was used and Bonferroni correction for multiple testing was
selected. Only results with Bonferroni-corrected for p < 0.05 are displayed. The
analysis was run based on molecular function (A) biological process (B) and cellular
component (C). n represents the number of hits matching the criteria. Number (#)
of hits represent the number of IntTox α-syn suppressors that map to this
annotation data category. Fold enrichment (fifth column) is calculated by the online
software based on the number of actual hits in comparison to the number of
expected hits (fourth column). Over (+) or under (-) represented denotes if the
specific category is higher or lower compared to expected values.
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Table 5. 14-3-3 protein isotypes that suppressed the IntTox a-synuclein toxicity
under glycerol-ethanol condition.
Gene
name

Protein name

Significance102

14-3-3β

14-3-3 protein β/α

Present in tangles in Alzheimer’s
disease

14-3-3𝛉

14-3-3 protein theta

Present in Lewy bodies in
Parkinson’s disease

14-3-3γ

14-3-3 protein gamma

Present in Lewy bodies in
Parkinson’s disease

14-3-3𝜻

14-3-3 protein zeta/delta

Present in Lewy bodies in
Parkinson’s disease

There is a total of seven 14-3-3 protein isotypes. Of the seven, six were included in
our human gene library. Of the six, four 14-3-3 proteins suppressed the a-syn
toxicity under glycerol-ethanol condition.
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3.2: To characterize the 14-3-3 isotype suppressors of IntTox a-synuclein toxicity
14-3-3 isotypes suppress the toxicity but do not reduce aggregate formation of IntTox

a-syn under glycerol-ethanol. We used all six 14-3-3 isotypes (4 suppressors and two
non-suppressors) to perform a spotting assay. Figure 26 shows that only four of the six
isotypes (b, q, g, and z) can suppress the toxicity of IntTox a-syn toxicity under glycerolethanol. Galactose was used as a control where no toxicity with IntTox a-syn was
observed. As shown in Aim 2, IntTox a-syn shows toxicity in galactose in a haploid
yeast strain. Hence, we performed spotting assays in the haploid condition without
GAL3A368V. Interestingly, the 14-3-3 suppressor isotypes did not suppress the toxicity in
galactose (Figure 27). Whether the suppressor isotypes instead enhance the toxicity of
IntTox a-syn in galactose condition requires further investigation.
Next, we quantified the proportion of cells containing a-syn aggregates in the
presence of 14-3-3 isotypes (Figure 28 A and B). 14-3-3q, 14-3-3g, and 14-3-3z did not
reduce the percentage of cells with aggregates; while 14-3-3b increased (p = 0.02) the
proportion of cells with aggregates. Further, the non-suppressor isotypes, 14-3-3s, and
14-3-3h did not increase the aggregates. We also observed that the protein expression
level of a-syn was not affected by the 14-3-3 suppressor subtypes (Figure 29 A and B).
14-3-3 isotypes do not increase the viability and respiratory competency of cells. We
predicted that the suppressors may increase the amount of viable and respiratorycompetent cells. However, the 14-3-3 isotypes did not significantly impact the viability,
or respiratory competency, of cells (Figure 30 A and B).
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Figure 26. Four 14-3-3 isotypes suppress the toxicity of IntTox a-synuclein in
glycerol-ethanol.
The W303 MATa strain containing IntTox a-syn was transformed with an empty vector
(pRS416-GAL) or 14-3-3 isotypes. Single diploid yeast colonies containing both IntTox
a-syn (with 14-3-3 isotypes) and GAL3A368V (W303 MATα strain) were grown overnight
in double selective 2% glucose media. The culture was washed twice with distilled water
and diluted to an OD600 of 1.0 and was spotted (left-most column). The diluted culture
was further serially diluted 10-fold and spotted four times. The dilution was repeated
until the last column on the right. The dilution is indicated by the tapering triangle bar on
the top. Cells were then spotted onto solid double selective agar plates containing 2%
glucose (negative control), 2% galactose (positive control), or 3% glycerol and 1%
ethanol, and incubated for 2–5 days.
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Figure 27. Four 14-3-3 isotypes do not suppress the toxicity of IntTox a-synuclein in
galactose.
The W303 MATa strain containing IntTox a-syn was transformed with an empty vector
(pRS416-GAL) or 14-3-3 isotypes. Single haploid yeast colonies containing both IntTox
a-syn (with 14-3-3 isotypes) were grown overnight in double selective 2% glucose
media. The culture was washed twice with distilled water and diluted to an OD600 of 1.0
and was spotted (left-most column). The diluted culture was further serially diluted 10fold and spotted four times; the dilution was repeated until the last column on the right.
The dilution is indicated by the tapering triangle bar on the top. Cells were then spotted
onto solid double selective agar plates containing 2% glucose (negative control), 2%
galactose (positive control), or 3% glycerol and 1% ethanol, and incubated for 2–5 days.
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Figure 28. 14-3-3β increases IntTox a-synuclein aggregates in glycerol-ethanol.
IntTox a-syn was transformed with an empty vector (pRS416-GAL) or 14-3-3 isotypes.
Single diploid yeast colonies containing both IntTox a-syn (W303 MATa strain) and
GAL3A368V (W303 MATα strain) were grown overnight in double selective 2% glucose
media. The culture was washed twice with distilled water and diluted to an OD600 of 1.0
and was grown in double selective 3% glycerol with 1% ethanol media and induced for
18 h. Cells were isolated and 3 µL of suspension was placed on a glass slide and
aggregates were viewed under the YFP channel. Scale bar: 5 µm. BF, bright field (A).
Quantification of the aggregates (B) was performed using ImageJ and verified by manual
counting. The experiments were repeated three times and a minimum of 200 cells were
counted for each isotype. Bars represent mean + SE. Dunnett’s test was performed to
compare each 14-3-3 isotype to the vector. *p < 0.05 and hence significantly different
compared to the vector. N.S., not significantly different compared to the vector.
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Figure 29. 14-3-3 suppressor isotypes do not reduce IntTox a-synuclein protein
expression in glycerol-ethanol.
Single diploid yeast colonies containing both IntTox a-syn (W303 MATa strain) and
GAL3A368V (W303 MATα strain) were grown overnight in double selective 2% glucose
media. IntTox a-syn was transformed with an empty vector (pRS416-GAL) or 14-3-3
isotypes. The culture was washed twice with distilled water and diluted to an OD600 of
1.0 and was grown in double selective 3% glycerol with 1% ethanol media and induced
for 18 h. Cell cultures at an OD600 of 1.0 (1 x 107 cells) were isolated and the protein was
extracted. SNCA encoding IntTox a-syn was tagged with YFP and an antibody against
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GFP was used. The loading control protein used was PGK1. (A) shows the blotting
images and (B) shows quantification of the bands. Image quantification was performed
using ImageJ. The experiment was repeated three times, and the bar graphs represent
mean + SE. Protein expression in the presence of vector was used as the reference value.
Dunnett’s test was performed to compare each 14-3-3 isotype to the vector. *p < 0.05 and
hence significantly different compared to the vector. N.S., not significantly different
compared to the vector.
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Figure 30. 14-3-3 suppressor isotypes do not increase viability or respiratory
competency in glycerol-ethanol.
Single diploid yeast colonies containing both IntTox a-syn (W303 MATa strain) and
GAL3A368V (W303 MATα strain) were grown overnight in double selective 2% glucose
media. IntTox a-syn has been transformed with an empty vector (pRS416-GAL) or 14-33 isotypes. The culture was washed twice with distilled water and diluted to an OD600 of
1.0 and was grown in double selective 3% glycerol with 1% ethanol media and induced
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for 18 h. Cells at an OD600 of 1.0 were harvested and diluted; 100 µL each of 10-4 dilution
and 10-5 dilution were plated on YPD and YPGE agar plates to determine the number of
viable (A) and respiratory-competent cells (B), respectively. Agar plates were incubated
for 2–3 days and single colonies were counted. Colony counts from the dilution that were
nearest to 100 were chosen. The colony counts were multiplied by the respective dilution
factor and used for statistical analysis. Dunnett’s test was performed to compare each 143-3 isotype to the vector. N.S., not significantly different compared to the vector. Y-axis,
logarithmic scale; OD, optical density.
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14-3-3 isotypes do not modify the mitochondrial structure or the disrupted membrane
potential signal. We next transformed the 14-3-3 plasmids into the yeast strains
containing pMitoLoc and examined the mitochondrial structure and membrane potential.
When we examined the mitochondria, we did not see a reduction in the dense
mitochondrial structures (Figure 31). Moreover, the 14-3-3 subtypes did not modify the
disrupted membrane potential. When we examined the IntTox a-syn aggregates, we
noticed that there were fewer than in the previous experiments (Figure 27). Hence, we
compared the proportion of aggregates between the two experiments and found that there
was a 12–71 percent difference between the two experiments. The highest difference in
the percentage of aggregates occurred with the empty vector (41% decrease) and 14-3-3β
(71% decrease).
14-3-3 isotypes do not decrease the ROS production and 14-3-3β decreases the
percentage of cells that accumulate ROS. Upon examining mitochondrial ROS with a
plate reader, the 14-3-3 suppressors did not significantly reduce ROS production (Figure
32). Further, under microscopic examination, no visible increase or decrease in ROS was
noted (Figure 33 A). All 14-3-3 suppressor isotypes had lower percentage of cells that
accumulates ROS, although only 14-3-3β was significant (p = 0.04) (Figure 33 B).
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Figure 31. 14-3-3 isotypes do not modify the mitochondrial structure or the
disrupted membrane potential signal.
The IntTox α-syn strain were transformed with pMitoLoc which has two (TFP and
mCherry) tags with mitochondrial targeting sequence. Teal (TFP) represents all
mitochondria; read (mCherry) represents only healthy mitochondria. Single diploid yeast
colonies containing both IntTox a-syn (W303 MATa strain) and GAL3A368V (W303 MATα
strain) were grown overnight in double selective 2% glucose media. IntTox a-syn has
been transformed with an empty vector (pRS416-GAL) or 14-3-3 isotypes. The culture
was washed twice with distilled water and diluted to an OD600 of 1.0 and grown in double
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selective 3% glycerol with 1% ethanol media and induced for 18 h. Cells were isolated
and 3 µL of suspensions were placed on a glass slide and viewed under the YFP, CFP
and Tx Red channels. SNCA encoding α-syn wasa tagged with YFP. CFP images were
obtained by Z-stack. Images of mitochondria were merged using ImageJ. Scale bar: 5
µm. BF, bright field.
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Figure 32. 14-3-3 isotypes do not decrease ROS production.
Single diploid yeast colonies containing both IntTox a-syn (W303 MATa strain) and
GAL3A368V (W303 MATα strain) were grown overnight in double selective 2% glucose
media. IntTox a-syn was transformed with an empty vector (pRS416-GAL) or 14-3-3
isotypes. The culture was washed twice with distilled water and diluted to an OD600 of
1.0 and grown in double selective 3% glycerol with 1% ethanol media and induced for 18
h. Cells were incubated with DHE for 20 min in the dark and absorbance was measured
at λex = 485 nm and λem = 620 nm. The amount of ROS generated was calculated as the
ratio of the absorbance to the OD600. Dunnett’s test was performed to compare each 14-33 isotype to the vector. N.S., not significantly different compared to the vector.
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Figure 33. 14-3-3β decreases the percentage of cells that accumulate ROS.
The same sample of cells from Figure 32 was used for microscopic imaging. Three
microliters of the cells were placed on the glass slide and viewed under the YFP (α-syn)
and Tx Red (ROS) channels. ROS, when generated in the cells reacts with DHE and
emits a red color; the intensity of the red color indicates the amount of ROS. (A) ROS
and α-syn in glycerol-ethanol at 18 h of induction. (B) Quantification of the cells that
accumulate ROS (bright red fluorescence in [A]). Percentage of cells that accumulate
ROS was calculated as the ratio of the number of bright red fluorescent cells to the total
number of cells. The experiments were repeated three times and the bars represent mean
+ SE. Dunnett’s test was performed to compare each 14-3-3 isotype to the vector. *p <
0.05 and hence significantly different compared to vector. N.S., not significantly different
compared to the vector. Scale bar: 5 µm. BF, bright field; ROS, reactive oxygen species.
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VI.

DISCUSSION

In Aim 1, we chose three GAL3 alleles - GAL3F237Y, GAL3A368V and GAL3S509P
and tested their ability to induce the GAL1 promoter under non-galactose conditions. We
used β-galactosidase assay to test the level of promoter induction. We also corroborated
the findings from the β-galactosidase assay using a yeast spotting assay. We found that
all three GAL3 alleles induced the GAL1 promoter in glycerol-ethanol condition (Figure
3), however, the combination of these alleles did not induce the promoter (Figure 4) as
the combinations failed to enable transition to a ‘closed active’ Gal3p conformation
(Figure 5). Based on α-syn as the model in the spotting assay, we chose to use GAL3A368V
for further experiments. Yet, when GAL3A368V was assessed in other non-galactose
conditions, including caloric restriction and nitrogen starvation conditions, we found that
it did not induce the GAL1 promoter in the presence of glucose (Figure 6). This finding
was verified by spotting assay using α-syn, FUS, TDP-43 and HTT103Q (Figure 7).
However, when glucose content was reduced from 0.5% to 0.1% and when the glucose
was replaced with raffinose, we saw rapid induction of the GAL1 promoter (Figure 8).
Under calorie restriction (0.1% glucose), raffinose and nitrogen starvation (2% raffinose),
IntTox and HiTox a-syn overexpression caused differential toxicity and aggregate
formation. Specifically, IntTox a-syn showed toxicity, however, did not exhibit
aggregate formation in raffinose conditions (Figure 9 and 10); while HiTox a-syn did
not induce toxicity yet showed aggregate formation under calorie restriction (Figure 9
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and 11). This is the first study showing the uncoupling of toxicity and aggregate
formation of a-syn. Results from Aim 1, therefore, show that GAL3A368V can be used to
study genes in any non-galactose condition lacking glucose.
We chose three GAL3 alleles from a previous publication75 where a haploid
condition was utilized and the WT GAL3 was deleted. To this end, we first examined the
GAL3 alleles in a diploid condition and then in the presence of WT GAL3. Our lab had
previously validated genetic screening in diploid conditions98 and thus performing a
screening with deletion of WT GAL3 from about 15,000 yeast strains containing human
genes seemed impractical. For the first time, we have shown that GAL3 alleles can be
constitutively active and induce the GAL1 promoter in diploid conditions in the presence
of two WT GAL3 (from the two haploid strains). Once we understood that GAL3A368V
activity need not be restricted to glycerol-ethanol but rather to any non-galactose
conditions, we extended our analysis to other conditions including, calorie restriction and
nitrogen starvation. We also found that GAL3 alleles are unable to induce the GAL1
promoter in the presence of low glucose concentrations (0.5%). This is likely attributable
to the significant suppressive function of glucose on the GAL1 promoter.77 Glucose
represses GAL1 expression by three primary mechanisms.76 Firstly, glucose acts on the
upstream activating sequence and reduces Gal4p (transcriptional activator) while
increasing Gal80p (repressor) expression. Secondly, Mig1p, a transcriptional repressor
binds to the upstream repression sequence and represses GAL1 expression in the presence
of glucose. Thirdly, glucose inhibits the transcription of GAL2 encoded galactose
permease and reduces the level of functional inducer in the cell. Thus, GAL3A368V was
unable to circumvent this multi-tactical repression mechanism by glucose.
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Additionally, we found that the combination of GAL3 alleles did not significantly
increase GAL1 promoter strength. Structural analysis of Gal3p showed that the mutations,
in combination, prevented the transition to the ‘closed active’ conformation of Gal3p.
F237 of Gal3p sits in a hydrophobic pocket that is comprised of F247, M403, L65, F414,
F418, and I245. A closed conformation will force the F237 from the hydrophobic pocket
to a more hydrophilic site. Similarly, substituting phenylalanine for tyrosine in F237Y
(i.e. a hydroxyl group) has the same result, effectively drawing the peptide out. The
position in which the F237 extends from the pocket is where S509 is located.
Alternatively, substituting serine for proline (S509P) prevents F237Y from popping out
of the hydrophobic pocket and, thus, the combination of alleles cancels the transition to a
closed conformation.73
Finally, the most interesting finding of this Aim was the discrepancy between
toxicity and aggregate formation observed with IntTox and HiTox a-syn overexpression
in non-galactose conditions. Previously, all studies involving a-syn report the presence of
cellular toxicity or neurodegeneration with the presence of a-syn inclusions.103 However,
here we are the first to comprehensively demonstrate that a-syn can augment or attenuate
toxicity irrespective of the presence of inclusions, depending on the growth conditions.
Although understanding this discrepancy requires further investigation, we hypothesize
potential causes for these observations. Under caloric restriction conditions, the lifespan
of yeast cells becomes extended and subsequently the decline of UPR is abrogated.104 In
addition, calorie restriction maintains autophagy (the cell’s recycling machinery) in
homeostasis by reducing Sir2 activity.94 Thus, it may be that under calorie restriction, the
cell’s protective mechanisms (UPR and autophagy) neutralize the presence of aggregates
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and reduce cellular toxicity. In case of raffinose condition, no aggregates were observed
although toxicity was apparent with IntTox a-syn. This may have been caused by
raffinose activating alternate signaling pathways that reduce ROS production and/or
cytochrome c release.105 Further experiments testing the level of ROS and cytochrome c
can help explain if these mechanisms are responsible for the absence of aggregates
despite the presence of toxicity. Reduction of ROS and cytochrome c will result in
reduction of mitochondrial stress. Reduced mitochondrial stress means functional
mitochondria and we know that a-syn requires a functional mitochondria in yeast to
produce toxicity.44 Thus, the protective signaling mechanisms activated under raffinose
likely reduces the mitochondrial stress to a level that can prevent aggregate formation but
not to a level that can suppress toxicity caused by IntTox a-syn overexpression.
In Aim 2, we saw that IntTox α-syn was toxic under glycerol-ethanol but not
under galactose in diploid yeast strains (Figure 13). Although we did not observe an
increase in α-syn protein expression (Figure 16) in the glycerol-ethanol condition that
would explain the higher toxicity, we did see an increase in the proportion of cells with αsyn aggregates under glycerol-ethanol (Figure 17) compared to galactose conditions, that
may provide a partial explanation for the observed toxicity. IntTox α-syn did not affect
the respiratory competency in galactose but rather affected it only under glycerol-ethanol
(Figure 19). We also observed dense mitochondrial structures predominantly under
glycerol-ethanol condition (Figure 20). Based on quantitative and microscopic
assessment, we concluded that increased ROS reading with IntTox α-syn overexpression
is due to increased percentage of cells that accumulate high-level of ROS (Figure 21 and
22). From Aim 2, it can be concluded that the increased toxicity of IntTox α-syn in
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glycerol-ethanol condition compared to galactose is due to increased aggregate
formation, decreased number of viable and respiratory-competent cells and the presence
of dense mitochondrial structures. The other parameters including protein expression
level, membrane potential, ROS production and presence of cells that accumulate ROS
did not differ significantly between the two conditions and thus, cannot explain the
increased toxicity in the glycerol-ethanol condition.
Under glycerol-ethanol, we saw that the toxicity of all genes – SNCA (IntTox and
HiTox), FUS, and TDP-43 – increased. a-syn affects the mitochondria in multiple ways
and reduces the respiratory cellular activity. Hsp60, a mitochondrial chaperone, mediates
FUS entry into the mitochondria and in transgenic flies, and thus, downregulation of
Hsp60 rescues mitochondrial defects and neurodegenerative phenotypes caused by FUS
overexpression.106 TDP-43 preferentially binds mitochondrial mRNAs of complex I
subunits ND3 and ND6 eventually causing complex I disassembly.107 In a transgenic
TDP-43 mutant mouse model, disrupting the mitochondrial localization of TDP-43
results in abrogation of mitochondrial dysfunction and neuronal loss. Thus, it is possible
that under glycerol-ethanol condition, there is an increase in toxicity of all genes that
affect the mitochondria.
We observed both toxicity and aggregates with IntTox a-syn in diploid glycerolethanol and haploid galactose strains. Further, the level of toxicity between the two
strains as determined via spotting and liquid growth assays, was similar. However, when
we compare the percentage of aggregates between the two strains, we see fewer in
haploid galactose conditions (37%) compared to glycerol-ethanol (56%). It is, therefore,
important to note that these two conditions cannot be directly compared and are not
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interchangeable with differing underlying mechanisms of toxicity associated with each.
Further, we observed that when IntTox a-syn is induced in haploid and diploid
conditions, toxicity is completely absent in diploid. A proteome quantification study
using stable-isotope labeling of amino acids in haploid and diploid yeast cell cultures
showed unaltered expression levels of approximately 4,500 proteins between haploid and
diploid wild-type yeast.108 Only a few proteins involved in pheromone signaling and cell
wall structure were upregulated in haploid yeast. We do not, however, understand
whether these subtle changes in protein levels are sufficient to suppress the toxic
phenotype of a-syn. A direct comparison of mitochondrial structure and mitochondriarelated functions including ROS production, cytochrome c release, apoptosis, and
mitochondrial membrane potential between haploid and diploid condition in the presence
of GAL3A368V and a-syn might help explain the differences in toxicity between the two
strains.
Under galactose condition, in contrast to what we hypothesized, we did not
observe reduced respiratory competency with a-syn overexpression. This result, along
with an absence in mitochondrial structure alterations in galactose conditions denotes that
a-syn does not affect the mitochondrial function under galactose to the same extent as in
glycerol-ethanol. If the mitochondria are not functioning at their full capacity, as in the
case of galactose, a-syn does not seem to affect the mitochondrial function.
Alternatively, in glycerol-ethanol, when cell survival is dependent on mitochondrial
function, a-syn reduces mitochondrial function as well as respiratory competency. The
N-terminal amphipathic domain of α-syn has been reported to be associated with
alterations in mitochondrial morphology and the activation of mitochondrial permeability
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transition pores.109 This was associated with a decrease in mitochondrial cardiolipin
content. Glycerol-ethanol may induce changes in mitochondrial structures and thus
becomes vulnerable to the action of a-syn.
Despite previous reports showing higher ROS production by a-syn under
galactose conditions,69,110 in our study, a-syn did not increase ROS production in the two
conditions. These previous studies measured ROS using quantitative techniques and as
such, the cells that accumulate ROS with red fluorescence may have been included in the
measurements and overlooked. Had we not performed the microscopic examination, we
too would have concluded that ROS production was indeed higher in the presence of asyn. Hence, plate reader measurements must be re-evaluated by excluding the
fluorescence emitted by the cells that accumulate ROS. Also, the reason as to why ROS
production was not increased by a-syn in our study remains unclear. The DHE dye that
we used primarily identifies cellular and not mitochondrial superoxide.111 The byproducts of this reaction include a ethidium (nonspecific redox product) and 2hydroxyethidium (adduct of superoxide).112 The wavelengths of these two by-products
overlap and thus, provide inconsistent results in a regular plate reader and in microscopic
images. The use of high-pressure liquid chromatography may serve to circumvent this
problem. Although we do not fully know which ROS species becomes induced by a-syn,
hydrogen peroxide rather than superoxide appears to dominate.113 Techniques to identify
different types of ROS would assist in better addressing these questions.
We measured the number of cells that accumulate ROS and found that they
increased in the presence of a-syn in both conditions although, there was no difference
between the two conditions. To identify the specific apoptotic stage of cells, further
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testing using Annexin V/propidium iodide (PI) co-staining is useful. This stain quantifies
externalization of phosphatidylserine, an early apoptotic event, and membrane
permeabilization, indicative for necrotic death. It also allows for the discrimination
between early apoptotic (Annexin V positive, PI negative), late apoptotic (Annexin V
positive, PI positive), and necrotic (Annexin V negative, PI positive) cells. Staining at
different time points during growth in the two conditions and their correlation with the
presence of aggregates can help predict the sequence of the two events.
YCA1 is the yeast orthologue of mammalian caspase; the deletion of YCA1
abolishes the ROS accumulation induced by a-syn, suggesting that caspase is the key
mediator in ROS production. We can, therefore, determine if deletion of YCA1 prevents
or reduces apoptosis in the glycerol-ethanol condition. Alternatively, pan-caspase
inhibitor Q-VD-OPh114 can be used to examine the role of caspase in apoptotic cell death
induced by a-syn in glycerol-ethanol. Nevertheless, the amount (< 25%) of apoptosis
alone cannot explain the increased toxicity in the glycerol-ethanol condition. Hence, it
can be concluded that mitochondrial function plays a dominant role in inducing apoptosis
and toxicity in glycerol-ethanol.
In Aim 3, using yeast mating technique validated in our lab,98 we screened 14,827
human gene clones (corresponding to 12,890 genes) to identify suppressors of IntTox αsyn in glycerol-ethanol. There were 184 hits in the screen, however, after performing a
confirmation step, only 87 remained. When this list was compared with the hits obtained
from the haploid galactose condition performed in our lab, we found that 43 of the 87 hits
were present only under glycerol-ethanol. Further, GO enrichment analysis of IntTox αsyn suppressor hits showed significant overexpression of genes related to the function of

109

RNA polymerase II (Table 4). Any process that activates or increases the frequency, rate
or extent of transcription from an RNA polymerase II promoter were overrepresented in
suppressors of IntTox α-syn. Genes associated with anterior-posterior pattern
specification were also overrepresented. Anterior-posterior pattern specification is a
process in which specific areas of cell differentiation are determined along the anteriorposterior axis during neuronal development. Additionally, homeobox proteins dominated
both RNA polymerase II and anterior-posterior pattern specification groups. Genes that
belong to nucleoplasm were overrepresented whereas genes that belonged to organelle
membrane were underrepresented among the confirmed suppressors.
Interestingly, among the 43 hits, four of the 14-3-3 isotypes (b, q, g, and z)
emerged as suppressors of IntTox α-syn only in glycerol-ethanol and not in galactose
condition (Table 5 and Figure 26 and 27). Whether 14-3-3 isotypes enhanced the
toxicity of IntTox α-syn in galactose must be confirmed in subsequent analyses.
Nevertheless, 14-3-3β increased the number of IntTox α-syn aggregates (Figure 28)
although this result was not consistent across other experiments. 14-3-3 suppressor
isotypes neither reduced protein expression levels (Figure 29) of IntTox a-syn nor
increased viability and respiratory competency in glycerol-ethanol (Figure 30).
Moreover, no changes in mitochondria was observed (Figure 31), and ROS production
was not decreased (Figure 32) by the 14-3-3 suppressors. However, 14-3-3β was found
to decrease the proportion of cells that accumulate ROS (Figure 33). This Aim unraveled
some unique patterns of suppressors – the involvement of RNA polymerase II, anteriorposterior axis morphogenesis and nucleus. Although we were unable to characterize how
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the four 14-3-3 proteins suppressed IntTox α-syn toxicity in glycerol-ethanol, we were
able to rule out certain mechanisms.
The overrepresentation of genes involved in RNA polymerase II function and
anterior-posterior axis specification highlights the fact that modification at the
transcriptional level and early neuronal development play key roles in suppressing the
toxicity of IntTox α-syn in glycerol-ethanol. Further, these groups were dominated by
homeobox proteins. Homeobox genes are a group of approximately 250 genes each
containing a 60-amino acid homeodomain that is responsible for DNA binding and
regulation of hindbrain morphogenesis and axial skeleton patterning by acting as
transcriptional regulators.115 Two of the homeobox protein suppressors, LHX4 and OTX1,
have been shown to be present in dopaminergic neuron progenitor cells in the midbrain
and to regulate their development.116,117 Homeobox proteins, EN-1 and EN-2, in addition
to regulating transcription also regulate mRNA translation. Specifically, in two (mutant
α-syn and MPTP toxin-induced) Parkinson’s disease model, EN-1 and EN-2 were shown
to regulate Ndufs1 and Ndufs3 translation, two mitochondrial complex I proteins, and
prevented dopaminergic neuron death in vivo.118 Thus, homeobox genes are dynamic in
that they not only regulate gene transcription but are also able to regulate translation of
mitochondrial proteins in dopaminergic neurons. Although it is unlikely that homeobox
proteins regulate the expression of the GAL1 promoter driven SNCA in yeast, the protein
levels of α-syn need to be examined to rule out this possibility. Alternatively, the
suppressor genes could alter the expression of other yeast genes, alleviating the toxicity
of α-syn.
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Four isotypes of 14-3-3 protein was found to suppress the toxicity of IntTox α-syn
in glycerol-ethanol. 14-3-3 proteins have 40% homology to α-syn, colocalize with a-syn
and accumulate in Lewy bodies in Parkinson’s disease brains.119 14-3-3 proteins play key
roles in neuronal cell division and differentiation through phosphorylation of mitogenactivated protein kinase kinase by activating gene transcription.120 Specifically, 14-3-3h
binds with aggregate prone oligomers of a-syn; while overexpression of a-syn sequesters
and downregulates 14-3-3h.121 When 14-3-3g, 14-3-3q, and 14-3-3e were overexpressed
in neuroglioma cells, a reduction in the number of aggregates was observed.122 We did
not observe such a reduction in the number of aggregates with any of the 14-3-3
suppressor isotypes. In fact, we saw an increase in the amount of aggregates with 14-33b. We also saw a variation in the percentage of aggregates between experiments. We are
unsure of the cause of such variations between experiments. It might be worth integrating
one or more copies of the 14-3-3 genes in the yeast genome to re-examine their effect on
α-syn aggregation.
Next, 14-3-3 proteins exhibit anti-apoptotic functions by binding to, and
sequestering, pro-apoptotic Bad.123,124 In our study, we saw that 14-3-3β reduced the
proportion of cells that accumulate ROS. Hence, the suppression of toxicity may be
partially explained by the anti-apoptotic effect of 14-3-3. This must be validated as yeast
does not contain the mammalian anti-apoptotic machinery. Specifically, YCA1, an
orthologue of caspase in yeast, can be deleted and the suppressive effect retested with 143-3β. Alternatively, a pan-caspase inhibitor, Q-VD-OPh,114 can be used to test the role of
apoptotic inhibition in the suppressive function of 14-3-3β.
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Finally, we did not see any changes in mitochondrial structure, membrane
potential, ROS production, viability or respiratory competency with 14-3-3 suppressor
proteins; thus, an alternate explanation for the suppressive effect must exist and may rely
on that information. As mentioned before, 14-3-3h, 14-3-3g, 14-3-3q, and 14-3-3e have
been shown, in in vitro and other models, to sequester a-syn and reduce the formation of
aggregates.120,121 It is interesting to see similar findings of a-syn toxicity suppression in a
simple eukaryotic cell, yeast. Although we do not know the exact mechanisms underlying
the suppressor effect of 14-3-3 isotypes in yeast, we speculate that a direct interaction
between the 14-3-3 isotypes and a-syn could be involved. The binary interaction can be
tested using yeast-two-hybrid assay. Alternatively, other conserved functions of 14-3-3 in
yeast might be at play. Such functions might be affected by carbon source, since the
suppressor effect was not observed on galactose. It would be interesting to determine if
14-3-3 was able to suppress the toxicity on raffinose condition to better understand if the
a-syn aggregation foci are involved. Finally, the proposed mechanisms need to
differentiate the suppressors from the non-suppressors that were identified.
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VII.

CONCLUSION

Three GAL3 alleles - GAL3F237Y, GAL3A368V and GAL3S509P - induced GAL1 promoter in
glycerol-ethanol condition, however, the combination of the alleles did not induce the
promoter. GAL3A368V did not induce GAL1 promoter in the presence of glucose. IntTox asyn induced toxicity in raffinose without aggregate formation. HiTox a-syn failed to
induce toxicity yet formed aggregates under caloric restriction. IntTox α-syn was toxic
under glycerol-ethanol yet not under galactose. IntTox α-syn protein levels were not
increased but the aggregates were increased in glycerol-ethanol compared to galactose.
Respiratory competency was reduced, while cell population that accumulated ROS was
increased by IntTox α-syn in glycerol-ethanol. By screening 14,827 human gene clones,
we identified 87 hits as suppressors of IntTox α-syn toxicity. GO enrichment analysis of
the suppressor hits showed significant overexpression of genes related to the function of
RNA polymerase II, anterior/posterior pattern specification and nucleoplasm. These three
categories were enriched with genes of the homeobox proteins pointing toward
transcriptional regulation playing a vital role in suppressing toxicity of IntTox α-syn in
glycerol-ethanol. Four of the 14-3-3 isotypes (b, q, g, and z) emerged as the suppressors
of IntTox α-syn only under glycerol-ethanol. 14-3-3β increased the number of aggregates
of IntTox α-syn. 14-3-3 suppressor isotypes neither reduced protein expression levels of
IntTox a-syn nor increased viability and respiratory competency in glycerol-ethanol.
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Mitochondrial structure was unchanged, and ROS production was not decreased by the
14-3-3 suppressors. 14-3-3β decreased the percentage of cells that accumulated ROS.
Our study obliterates the limitation of performing screening only under galactose
condition. Future studies should focus on pinpointing the difference in transcription and
translation between galactose and glycerol-ethanol conditions since the parameters tested
did not provide a clear answer. Although yeast is a single eukaryotic cell with no
neurons, it still possesses the conserved cellular biology that underpins Parkinson’s
disease pathology. Therapeutic targets identified in prior α-syn yeast screening analyses
have been validated in higher organisms highlighting the relevance of this system in
studying Parkinson’s disease. Although there are aspects of this disease which are beyond
the scope of yeast, with the advancement of system and computational biology, largescale yeast genetic data on a-syn and Parkinson’s disease can be efficiently analyzed and
translated to humans.
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